Modified fc domains and uses thereof

WO2026227074A3PCT designated stage Publication Date: 2026-11-19KAIGENE INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/025443
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-04-25
Filing Date
2026-04-27
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current therapies for autoimmune diseases, such as B-cell depletion and anti-FcRn monoclonal antibodies, require frequent administration and have delayed onset of action, necessitating a need for prolonged suppression of pathogenic IgG antibodies and selective inhibition of autoantibody-producing B cells.

Method used

Development of a modified Fc domain with increased binding affinity to FcRn and FcyRIIB, incorporated into fusion proteins or antibodies, to enhance cellular uptake and degradation of autoantibodies and autoantigens, particularly by liver sinusoidal endothelial cells.

Benefits of technology

The modified Fc domain achieves prolonged suppression of pathogenic antibodies and autoantigens, providing effective and sustained therapeutic effects with reduced frequency of administration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026025443_19112026_PF_FP_ABST
    Figure US2026025443_19112026_PF_FP_ABST
Patent Text Reader

Abstract

Provided are modified Fc domain that has increased binding affinity to both FcRn and FcγRIIB or a fusion protein including the modified Fc domain. These modified Fc domains, fusion proteins or antibodies can be suitably use for treating diseases such as autoimmune diseases.
Need to check novelty before this filing date? Find Prior Art

Description

MODIFIED FC DOMAINS AND USES THEREOFCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit under 35 U.S.C. 119(e) of U.S. Provisional Application No. 63 / 795,196, filed April 25, 2025, which is hereby incorporated by reference in its entirety.BACKGROUND

[0002] Neonatal Fc receptors (FcRn), a widespread atypical receptor for the Fc region of gamma globulin, is found on diverse cells such as epithelial cells and within secondary lymphoid organs like the spleen, as well as the placenta. Originally discovered for its role in transferring maternal IgG, it also extends the lifespan of IgG in circulation by saving it from lysosomal breakdown in endothelial cells, aids in macrophage phagocytosis of IgG-coated antigens, and helps start immune responses by handling immune complexes in lymphoid tissues. FcRn does not interact with other immunoglobulin types but is known to bind albumin, therefore preventing its catabolism in lysosomes and extending its presence in the bloodstream. (Krystalyn E. Hudson et al., Transfusion. (2021)61(5): 1350-1354)).

[0003] The interaction between antibodies and FcRn is critical for maintaining the longevity of antibodies and related therapies in our blood. Composed of an MHC class I-like a domain along with a 02-microglobulin unit, FcRn binds to unique parts of the antibody Fc domain, distinct from Fey receptor binding sites. FcRn resides in several bodily regions, but it's primarily important in the vascular endothelium, kidneys, and the blood-brain barrier.

[0004] Fc-gamma-IIB (FcyRIIB) is the only FcyR expressed on B cells. Interaction of the antibody Fc region with FcyRIIB has been reported to suppress the primary immune response of B cells. Furthermore, it is reported that when FcyRIIB on B cells and a B cell receptor (BCR) are cross-linked via an immune complex in blood, B cell activation is suppressed, and antibody production by B cells is suppressed. (Holly M. Horton et al., J Immunol (2011) 186 (7): 4223-4233). In this immunosuppressive signal transduction mediated by BCR and FcyRIIB, the immunoreceptor tyrosine-based inhibitory motif (ITIM) contained in the intracellular domain of FcyRIIB is necessary. When ITIM is phosphorylated upon signaling, SH2-containing inositolpolyphosphate 5-phosphatase (SHIP) is recruited, transduction of other activating FcyR signal cascades is inhibited, and inflammatory immune response is suppressed. Furthermore, aggregation of FcyRIIB alone has been reported to transiently suppress calcium influx due to BCR cross-linking and B cell proliferation in a BCR-independent manner without inducing apoptosis of IgM-producing B cells.

[0005] Modified Fc domains are currently being developed in the form of anti-FcRn monoclonal antibodies and engineered Fc fragments and are utilized to reduce IgG levels — including pathogenic autoantibodies — in patients with autoimmune diseases. In some cases, FcRn-targeting products may require weekly administration to maintain a clinically meaningful IgG reduction (e.g., approximately 50% reduction from baseline), due to limited duration of action.

[0006] Separately, B-cell depletion therapies are employed to reduce autoantibody production by targeting the source of antibody generation. While effective, these therapies exhibit delayed onset of action, often taking several weeks to demonstrate clinical benefit. Nonetheless, once established, the therapeutic effect — particularly autoantibody suppression — can persist for over 6 months.

[0007] Given these limitations, there is a need for novel strategies that enable both prolonged suppression of pathogenic IgG antibodies, autoantibodies, or antigens (e.g., IgA autoantigens) and selective inhibition of autoantibody-producing B cells, thereby overcoming the shortcomings of current therapies.SUMMARY

[0008] Provided in the present disclosure is a modified Fc domain that has increased binding affinity to FcRn and FcyRIIB as compared to wild type Fc domain, thereby increasing cellular uptake by FcRn-expressing endothelial cells, promoting effective delivery and degradation of antigens, autoantibodies (e.g., IgG autoantibodies), or autoantigens and enabling preferential uptake by liver sinusoidal endothelial cells, which highly express FcyRIIB.

[0009] Also provided herein is a fusion protein having the modified Fc domain.

[0010] Also provided herein is an antibody or fusion protein comprising a specific antigen-, autoantibody- or autoantigen-binding domain and the modified Fc domain, allowing selectivetargeting and degradation of pathogenic autoantibodies or autoantigens in circulation. The antibody neutralizes and depletes specific pathogenic antigens, autoantibodies, or autoantigens.

[0011] In one aspect, provided herein is a modified Fc domain that has increased binding affinity to FcRn and FcyRIIB as compared to wild type Fc domain.

[0012] In certain embodiments, the modified Fc domain comprises one or more amino acid mutations selected from the group consisting of: (i) an aspartic acid (D) substitution or amino acid deletion at amino acid position 236 (236D or A236), (ii) an aspartic acid (D) substitution at amino acid position 237 (237D), (iii) an aspartic acid (D) substitution at amino acid position 238 (238D), (iv) a tyrosine (Y), or a tryptophan (W) substitution at amino acid position 252 (252Y or 252W), (v) a threonine (T) substitution at amino acid position 254 (254T), (vi) a glutamic acid (E) substitution at amino acid position 256 (256E), (vii) a glutamic acid (E) substitution at amino acid position 267 (267E), (viii) a proline (P) substitution at amino acid position 308 (308P), (ix) a phenylalanine (F) substitution at amino acid position 328 (328F), (x) a lysine (K) or an arginine (R) substitution at amino acid position 433 (433K or 433R), and (xi) a tyrosine (Y), a tryptophan (W), a phenylalanine (F), or an arginine (R) substitution at amino acid position 434 (434Y, 434W, 434F, or 434R).

[0013] In certain embodiments, the modified Fc domain comprises: (a) one or more mutations selected from the group consisting of (i) 252Y or 252W, (ii) 254T, (iii) 256E, (iv) 308P, (v) 433K or 433R, and (vi) 434Y, 434W, 434F, or 434R; and (b) one or more mutations selected from the group consisting of (i) 236D or A236, (ii) 237D, (iii) 238D, (iv) 267E, (v) 308P, and (vi) 328F.

[0014] In certain embodiments, the modified Fc domain is derived from a human IgGl, IgG2, IgG3, or IgG4 Fc domain. In certain embodiments, the modified Fc domain is derived from a human IgGl Fc domain.

[0015] In certain embodiments, the modified Fc domain comprises a set of mutations selected from the group consisting of (i) M252Y / S254T / T256E / V308P / N434Y; (ii) M252Y / S254T / T256E / H433K / N434F; (iii) M252Y / S254T / T256E; (iv) M252Y / S254T / T256E / N434W; (v) M252Y / V308P / N434Y; (vi) M252Y / S254T / T256E / V308P / N434F; (vii) M252Y / S254T / T256E / V308P / H433R / N434Y; (viii) M252W / V308P / H433R / N434Y; (ix) M252W / V308P / N434F; (x) M252W / N434W; (xi)S267E / L328F; (xii) G236D / S267E; (xiii) G236D / L328F; (xiv) AG236 / S267E; (xv) G237D / P238D / L328F: and (xvi) G236D / G237D / P238D / L328F.

[0016] In certain embodiments, the modified Fc domain comprises (a) a first set of mutations selected from the group consisting of: (i) M252Y / S254T / T256E / V308P / N434Y; (ii) M252Y / S254T / T256E / H433K / N434F; (iii) M252Y / S254T / T256E; (iv) M252Y / S254T / T256E / N434W; (v) M252Y / V308P / N434Y; (vi) M252Y / S254T / T256E / V308P / N434F; (vii) M252Y / S254T / T256E / V308P / H433R / N434Y; (viii) M252W / V308P / H433R / N434Y; (ix) M252W / V308P / N434F; and (x) M252W / N434W; and (b) a second set of mutations selected from the group consisting of: (i) S267E / L328F; (ii) G236D / S267E; (iii) G236D / E328F; (iv) AG236 / S267E; (v) G237D / P238D / E328F; and (vi) G236D / G237D / P238D / L328F.

[0017] In certain embodiments, the modified Fc domain comprises a set of mutations selected from the group consisting of (i) M252Y / S254T / T256E / V308P / N434Y and S267E / L328F; (ii) M252Y / S254T / T256E / H433K / N434F and S267E / L328F; (iii) M252Y / S254T / T256E and S267E / L328F; (iv) M252Y / S254T / T256E / N434W and S267E / L328F; (v) M252Y / V308P / N434Y and S267E / L328F; (vi) M252Y / S254T / T256E / V308P / N434F and S267E / L328F; (vii) M252Y / S254T / T256E / V308P / H433R / N434Y and S267E / L328F; (viii) M252W / V308P / H433R / N434Y and S267E / L328F; (ix) M252W / V308P / N434F and S267E / L328F; (x) M252W / N434W and S267E / L328F; (xi) M252Y / S254T / T256E / N434W and G236D / S267E; (xii) M252W / V308P / N434F and G236D / S267E; (xiii) M252Y / S254T / T256E / V308P / N434Y and G236D / L328F; (xiv) M252Y / S254T / T256E / V308P / N434Y and AG236 / S267E; (xv) M252Y / S254T / T256E / N434W and G237D / P238D / L328F; and (xvi) M252Y / S254T / T256E / N434W and G236D / G237D / P238D / L328F.

[0018] In certain embodiments, the modified Fc domain comprises mutations of: (i) M252Y / S254T / T256E / V308P / N434Y and S267E / L328F; or (ii) M252Y / S254T / T256E / H433K / N434F and S267E / L328F.

[0019] In certain embodiments, the modified Fc domain lacks an asialoglycoprotein receptor (AS GPR) -binding moiety. In certain embodiments, the modified Fc domain further comprises one or more members selected from the group consisting of a leucine (L) at amino acid position 234, a leucine (L) at amino acid position 235, and a proline (P) at amino acid position 329. Incertain embodiments, the modified Fc domain further comprises a phenylalanine (F) at position 243, a valine (V) at position 264, or both. In certain embodiments, the modified Fc domain further comprises one or more members selected from the group consisting of a Threonine (T) at amino acid position 250, a methionine (M) at amino acid position 428, an asparagine (N) at amino acid position 434, and an asparagine (N) at amino acid position 325.

[0020] In certain embodiments, the modified Fc domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 4-19 or a peptide having at least 80%, at least 90%, or at least 95% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 4-19. In certain embodiments, the modified Fc domain has an amino acid sequence selected from the group consisting of SEQ ID NOs: 4-19.

[0021] In certain embodiments, the modified Fc domain comprises at most 8 amino acid substitutions as compared to the wild-type Fc domain. In certain embodiments, the modified Fc domain comprises at most 7 amino acid substitutions as compared to the wild-type Fc domain.

[0022] In certain embodiments, the modified Fc domain is a heterodimer. In certain embodiments, the modified Fc domain further comprises knob-into-hole mutations in its respective chains. In certain embodiments, the knob-into-hole mutations include T366W in one chain, and T366S / L368A / Y407V in the other chain. In certain embodiments, the modified Fc domain comprises the amino acid sequence pair of SEQ ID NOs: 68 / 45 or 70 / 49, or an amino acid sequence pair having at least 80% sequence identity to the amino acid sequence pair of SEQ ID NO: 68 / 45 or 70 / 49. In certain embodiments, the modified Fc domain further comprises R292C and V302C. In certain embodiments, the modified Fc domain comprises the amino acid sequence pair selected from the group consisting of SEQ ID NO: 71 / 54, 72 / 56, 73 / 58, 74 / 60, 75 / 62 and 76 / 64, or an amino acid sequence pair having at least 80% sequence identity thereto.

[0023] In one aspect, provided herein is a modified Fc domain that has increased binding affinity to FcRn and FcyRIIB as compared to wild type Fc domain, wherein the modified Fc domain comprises: (i) a tyrosine (Y) substitution at amino acid position 252, (ii) a threonine (T) substitution at amino acid position 254, (iii) a glutamic acid (E) substitution at amino acid position 256, (iv) a lysine (K) substitution at amino acid position 433, (v) a phenylalanine (F) substitution at amino acid position 434, (vi) a glutamic acid (E) substitution at amino acid position 267, (vii) a phenylalanine (F) substitution at amino acid position 328, and (viii) aphenylalanine (F) at position 243, a valine (V) at position 264, or both, according to EU index as in Kabat.

[0024] In certain embodiments, the modified Fc domain comprises a leucine (L) at amino acid position 234. In certain embodiments, the modified Fc domain comprises a leucine (L) at amino acid position 235. In certain embodiments, the modified Fc domain comprises a proline (P) at amino acid position 329. In certain embodiments, the modified Fc domain comprises a threonine (T) at amino acid position 250. In certain embodiments, the modified Fc domain comprises a methionine (M) at amino acid position 428. In certain embodiments, the modified Fc domain comprises an asparagine (N) at amino acid position 325. In certain embodiments, the modified Fc domain comprises at most 8 amino acid substitutions as compared to the wild-type Fc domain. In certain embodiments, the modified Fc domain comprises at most 7 amino acid substitutions as compared to the wild-type Fc domain.

[0025] In one aspect, provided herein is a modified Fc domain that has increased binding affinity to FcRn and FcyRIIB as compared to wild type Fc domain, wherein the modified Fc domain comprises: (i) a tyrosine (Y) substitution at amino acid position 252, (ii) a threonine (T) substitution at amino acid position 254, (iii) a glutamic acid (E) substitution at amino acid position 256, (iv) a proline (P) substitution at amino acid position 308, (v) a tyrosine (Y) substitution at amino acid position 434, (vi) a glutamic acid (E) substitution at amino acid position 267, and (vii) a phenylalanine (F) substitution at amino acid position 328.

[0026] In certain embodiments, the modified Fc domain comprises one or more members selected from the group consisting of a leucine (L) at amino acid position 234, a leucine (L) at amino acid position 235, and a proline (P) at amino acid position 329. In certain embodiments, the modified Fc domain comprises one or more members selected from the group consisting of a threonine (T) at amino acid position 250, a methionine (M) at amino acid position 428, and an asparagine (N) at amino acid position 325. In certain embodiments, the modified Fc domain comprises at most 8 amino acid substitutions as compared to the wild-type Fc domain. In certain embodiments, the modified Fc domain comprises at most 7 amino acid substitutions as compared to the wild-type Fc domain.

[0027] In one aspect, provided herein is a fusion protein comprising the modified Fc domain described herein.

[0028] In certain embodiments, the fusion protein further comprises an antigen-binding domain fused to the modified Fc domain. In certain embodiments, the fusion protein further comprises an autoantibody binding domain fused to the modified Fc domain. In certain embodiments, the autoantibody binding domain is fused to C-terminus of the modified Fc domain via a peptide linker. In certain embodiments, the autoantibody binding domain has binding specificity to autoantibodies against NC16A region of human BP180. In certain embodiments, the autoantibody binding domain comprises the amino acid sequence of SEQ ID NO: 50 or 83. In certain embodiments, the fusion protein further comprises a pair of first chain / second chain of the sequences selected from the group consisting of SEQ ID NOs: 53 / 54, 55 / 56, 57 / 58, 59 / 60, 61 / 62, 63 / 64, 84 / 85, 86 / 87, 88 / 89, 90 / 91, 92 / 93, 94 / 95, and 96 / 97.

[0029] In certain embodiments, the autoantibody binding domain is fused to C-terminus of the modified Fc domain. In certain embodiments, the fusion protein further comprises an autoantigen binding domain fused to the modified Fc domain. In certain embodiments, the autoantigen binding domain is fused to C-terminus of the modified Fc domain via a peptide linker. In certain embodiments, the autoantibody binding domain has binding specificity to the Fc region of human IgAl (hlgAl). In certain embodiments, the fusion protein comprises a heavy chain variable region (VH) having the sequence of SEQ ID NO: 81 and a light chain variable region (VL) having the sequence of SEQ ID NO: 82. In certain embodiments, the fusion protein comprises a combination of light chain / first heavy chain / second heavy chain of the sequence of SEQ ID NO: 37 / 44 / 45 or 37 / 48 / 49.

[0030] In one aspect, provided herein is an antibody that specifically binds to human IgAl (hlgAl), wherein the antibody comprises: a heavy chain variable region comprising a heavy chain complementarity determining region 1 (CDRH1), a heavy chain complementarity determining region 2 (CDRH2), and a heavy chain complementarity determining region 3 (CDRH3) of the heavy chain variable region having polypeptide sequence as set forth in SEQ ID NO: 81; a light chain variable region comprising a light chain complementarity determining region 1 (CDRL1), a light chain complementarity determining region 2 (CDRL2), and a light chain complementarity determining region 3 (CDRL3) of the light chain variable region having polypeptide sequence as set forth in SEQ ID NO: 82; and a modified Fc domain that has increased binding affinity to FcRn and FcyRIIB as compared to wild type Fc domain, wherein the modified Fc domain comprises: (i) a tyrosine (Y) substitution at amino acid position 252, (ii) a threonine (T) substitution at amino acid position 254, (iii) a glutamic acid (E) substitutionat amino acid position 256, (iv) a lysine (K) substitution at amino acid position 433, (v) a phenylalanine (F) substitution at amino acid position 434, (vi) a glutamic acid (E) substitution at amino acid position 267, and (vii) a phenylalanine (F) substitution at amino acid position 328.

[0031] In certain embodiments, the antibody comprises a heavy chain variable region (VH) that comprises the amino acid sequence of SEQ ID NO: 81, and a light chain variable region (VL) that comprises the amino acid sequence of SEQ ID NO: 82. In certain embodiments, the antibody lacks an asialoglycoprotein receptor (ASGPR)-binding moiety. In certain embodiments, the modified Fc domain comprises one or more members selected from the group consisting of a leucine (L) at amino acid position 234, a leucine (L) at amino acid position 235, and a proline (P) at amino acid position 329. In certain embodiments, the modified Fc domain comprises a phenylalanine (F) at position 243, a valine (V) at position 264, or both. In certain embodiments, the modified Fc domain comprises one or more members selected from the group consisting of a threonine (T) at amino acid position 250, a methionine (M) at amino acid position 428, an asparagine (N) at amino acid position 434, and an asparagine (N) at amino acid position 325. In certain embodiments, the modified Fc domain comprises at most 8 amino acid substitutions as compared to the wild-type Fc domain. In certain embodiments, the modified Fc domain comprises at most 7 amino acid substitutions as compared to the wild-type Fc domain.

[0032] In one aspect, provided herein is an antibody that specifically binds to human IgAl (hlgAl), wherein the antibody comprises: a heavy chain variable region comprising a heavy chain complementarity determining region 1 (CDRH1), a heavy chain complementarity determining region 2 (CDRH2), and a heavy chain complementarity determining region 3 (CDRH3) of the heavy chain variable region having polypeptide sequence as set forth in SEQ ID NO: 81; a light chain variable region comprising a light chain complementarity determining region 1 (CDRL1), a light chain complementarity determining region 2 (CDRL2), and a light chain complementarity determining region 3 (CDRL3) of the light chain variable region having polypeptide sequence as set forth in SEQ ID NO: 82; and a modified Fc domain that has increased binding affinity to FcRn and FcyRIIB as compared to wild type Fc domain, wherein the modified Fc domain comprises: (i) a tyrosine (Y) substitution at amino acid position 252, (ii) a threonine (T) substitution at amino acid position 254, (iii) a glutamic acid (E) substitution at amino acid position 256, (iv) a proline (P) substitution at amino acid position 308, (v) atyrosine (Y) substitution at amino acid position 434, (vi) a glutamic acid (E) substitution at amino acid position 267, and (vii) a phenylalanine (F) substitution at amino acid position 328.

[0033] In certain embodiments, the antibody comprises a heavy chain variable region (VII) that comprises the amino acid sequence of SEQ ID NO: 81, and a light chain variable region (VL) that comprises the amino acid sequence of SEQ ID NO: 82. In certain embodiments, the antibody lacks an asialoglycoprotein receptor (ASGPR)-binding moiety. In certain embodiments, the modified Fc domain comprises one or more members selected from the group consisting of a leucine (L) at amino acid position 234, a leucine (L) at amino acid position 235, and a proline (P) at amino acid position 329. In certain embodiments, the modified Fc domain comprises a phenylalanine (F) at position 243, a valine (V) at position 264, or both. In certain embodiments, the modified Fc domain comprises one or more members selected from the group consisting of a threonine (T) at amino acid position 250, a methionine (M) at amino acid position 428, an asparagine (N) at amino acid position 434, and an asparagine (N) at amino acid position 325. In certain embodiments, the modified Fc domain comprises at most 8 amino acid substitutions as compared to the wild-type Fc domain. In certain embodiments, the modified Fc domain comprises at most 7 amino acid substitutions as compared to the wild-type Fc domain.

[0034] In one aspect, provided herein is a fusion protein that specifically binds to autoantibodies against NC16A region of human BP 180, wherein the fusion protein comprises: an autoantibody binding region comprising the amino acid sequence of SEQ ID NO: 50; and a modified Fc domain that has increased binding affinity to FcRn and I cy R II B as compared to wild type Fc domain, wherein the modified Fc domain comprises: (i) a tyrosine (Y) substitution at amino acid position 252, (ii) a threonine (T) substitution at amino acid position 254, (iii) a glutamic acid (E) substitution at amino acid position 256, (iv) a proline (P) substitution at amino acid position 308, (v) a tyrosine (Y) substitution at amino acid position 434, (vi) a glutamic acid (E) substitution at amino acid position 267, and (vii) a phenylalanine (F) substitution at amino acid position 328.

[0035] In certain embodiments, the fusion protein lacks an asialoglycoprotein receptor (AS GPR) -binding moiety. In certain embodiments, the modified Fc domain comprises one or more members selected from the group consisting of a leucine (L) at amino acid position 234, a leucine (L) at amino acid position 235, and a proline (P) at amino acid position 329. In certain embodiments, the modified Fc domain comprises a phenylalanine (F) at position 243, a valine (V) at position 264, or both. In certain embodiments, the modified Fc domain comprises one ormore members selected from the group consisting of a threonine (T) at amino acid position 250, a methionine (M) at amino acid position 428, an asparagine (N) at amino acid position 434, and an asparagine (N) at amino acid position 325. In certain embodiments, the modified Fc domain comprises at most 8 amino acid substitutions as compared to the wild-type Fc domain. In certain embodiments, the modified Fc domain comprises at most 7 amino acid substitutions as compared to the wild-type Fc domain.

[0036] In one aspect, provided herein is a pharmaceutical composition comprising the modified Fc domain, the fusion protein, or the antibody described herein; and a pharmaceutically acceptable carrier.

[0037] In one aspect, provided herein is a polynucleotide encoding the modified Fc domain, the fusion protein, or the antibody described herein. In certain embodiments, a vector comprises the polynucleotide. In certain embodiments, an isolated cell comprises the polynucleotide or the vector.

[0038] In one aspect, provided herein is a method of producing the modified Fc domain, the fusion protein, or the antibody described herein, comprising incubating the isolated cell under a condition for the isolated cell to express the modified Fc domain, the fusion protein, or the antibody.

[0039] In one aspect, provided herein is a method of treating an autoimmune disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the modified Fc domain, the fusion protein, or the antibody described herein. In certain embodiments, the autoimmune disease is an IgA- mediated disorder, or anti-NC16A autoantibody-mediated disorder. In certain embodiments, the IgA-mediated disorder comprises IgA nephropathy (IgAN), IgA vasculitis (Henoch-Schbnlein purpura), linear IgA bullous dermatosis, dermatitis herpetiformis, IgA pemphigus, or IgA autoimmune hemolytic anemia. In certain embodiments, the anti-NC16A autoantibody-mediated disorder comprises autoimmune blistering disease. In certain embodiments, the autoimmune blistering disease comprises bullous pemphigoid, pemphigoid gestationis, mucous membrane pemphigoid, or drug induced bullous pemphigoid disease or disorder.BRIEF DESCRIPTION OF THE DRAWINGS

[0040] FIG. 1A is a graph showing the results of a flow cytometry experiment comparing the hlgAl internalization properties of HISA43 with modified Fc fragments in CHO-Kl / FcRn cells.

[0041] FIG. IB is a graph showing the results of a flow cytometry experiment comparing the hlgAl internalization properties of HISA43 with modified Fc fragments in CHO-KI-FcyRIIB cells.

[0042] FIG. 2A is a graph showing the results of a B cell inhibition assay for IgA+B cells evaluating the inhibitory effect of HIS A43 with modified Fc fragments.

[0043] FIG.2B is a graph showing the results of a B cell inhibition assay for entire B cells evaluating the inhibitory effect of HIS A43 with modified Fc fragments.

[0044] FIG.3 is a graph of the average hlgAl profiles in serum upon IV administration of HISA43 with modified Fc fragments.

[0045] FIG.4A is a graph showing the results of a flow cytometry experiment comparing the hFcRn and hFcyRIIB binding properties of NC16A-Fc fusion constructs in CHO-Kl / FcRn cells.

[0046] FIG.4B is a graph showing the results of a flow cytometry experiment comparing the hFcRn and hFcyRIIB binding properties of NC16A-Fc fusion constructs in CHO-Kl-FcyRIIB cells.

[0047] FIG. 5 illustrates example structures of the modified Fc domain within the fusion proteins described herein (Format 1-4).DETAILED DESCRIPTIONDefinitions

[0048] It is to be noted that the term “a” or “an’’ entity refers to one or more of that entity; for example, “an antibody,” is understood to represent one or more antibodies. As such, the terms “a” (or “an”), “one or more,” and “at least one” can be used interchangeably herein.

[0049] The term “about" or “approximately” means within about 20%, such as within about 10%, within about 5%, or within about 1% or less of a given value or range.

[0050] The term “polypeptide" refers to any polymeric chain of amino acids and encompasses native or artificial proteins, polypeptide analogs or variants of a protein sequence, or fragments thereof, unless otherwise contradicted by context. A polypeptide may be monomeric or polymeric; that is, the term encompasses a protein having one or more covalently coupled, or noncovalently coupled, polypeptide chains. A polypeptide fragment comprises at least about 5 contiguous amino acids, at least about 10 contiguous amino acids, at least about 15 contiguous amino acids, or at least about 20 contiguous amino acids, for example.

[0051] As used herein, an “antibody” or “antigen-binding polypeptide" refers to a polypeptide or a polypeptide complex that specifically recognizes and binds to an antigen. An antibody can be a whole antibody and any antigen binding fragment or a single chain thereof. Thus the term “antibody” includes any protein or peptide containing molecule that comprises at least a portion of an immunoglobulin molecule having biological activity of binding to the antigen. Examples of such include, but are not limited to a complementarity determining region (CDR) of a heavy or light chain or a ligand binding portion thereof, a heavy chain or light chain variable region, a heavy chain or light chain constant region, a framework (FR) region, or any portion thereof, or at least one portion of a binding protein.

[0052] The terms “antibody fragment” or “antigen-binding fragment”, as used herein, is a portion of an antibody such as F(ab’)2. F(ab)2, Fab’, Fab, Fv, scFv, diabody and the like.Regardless of structure, an antibody fragment binds with the same antigen that is recognized by the intact antibody. The term “antibody fragment” includes aptamers, spiegelmers, and diabodies. The term “antibody fragment” also includes any synthetic or genetically engineered protein that acts like an antibody by binding to a specific antigen to form a complex.

[0053] A “Fab” with regard to an antibody refers to a monovalent antigen-binding fragment of the antibody consisting of a single light chain (both variable and constant regions) bound to the variable region and first constant region of a single heavy chain by a disulfide bond. Fab can be obtained by papain digestion of an antibody at the residues proximal to the N-terminus of the disulfide bond between the heavy chains of the hinge region. A “Fab”’ refers to a Fab fragment that includes a portion of the hinge region, which can be obtained by pepsin digestion of an antibody at the residues proximal to the C-terminus of the disulfide bond between the heavy chains of the hinge region and thus is different from Fab in a small number of residues (including one or more cysteines) in the hinge region.

[0054] A “F(ab’)2 ” refers to a dimer of Fab’ that comprises two light chains and part of the two heavy chains.

[0055] A “single-chain variable fragment’’ or “scFv’’ refers to a fusion protein of the variable regions of the heavy (VH) and light chains (VT.) of immunoglobulins. In some aspects, the regions are connected with a short linker peptide of ten to about 25 amino acids. The linker can be rich in glycine for flexibility, as well as serine or threonine for solubility, and can either connect the N-terminus of the VH with the C-terminus of the VL, or vice versa. This protein retains the specificity of the original immunoglobulin, despite removal of the constant regions and the introduction of the linker. ScFv molecules are known in the art and are described, e.g., in US patent 5,892,019.

[0056] The term antibody encompasses various broad classes of polypeptides that can be distinguished biochemically. Those skilled in the art will appreciate that heavy chains are classified as gamma, mu, alpha, delta, or epsilon (y, p. a, 5, E) with some subclasses among them (e.g., y 1- y4). It is the nature of this chain that determines the “class” of the antibody as IgG, IgM, IgA IgG, or IgE, respectively. The immunoglobulin subclasses (isotypes) e.g., IgGi, IgG2, IgG- IgG4, IgGs, etc. are well characterized and are known to confer functional specialization. Modified versions of each of these classes and isotypes are readily discernable to the skilled artisan in view of the instant disclosure and, accordingly, are within the scope of the instant disclosure. All immunoglobulin classes are clearly within the scope of the present disclosure, the following discussion will generally be directed to the IgG class of immunoglobulin molecules. With regard to IgG, a standard immunoglobulin molecule comprises two identical light chain polypeptides of molecular weight approximately 23,000 Daltons, and two identical heavy chain polypeptides of molecular weight 53,000-70,000. The four chains are typically joined by disulfide bonds in a “Y” configuration wherein the light chains bracket the heavy chains starting at the mouth of the “Y” and continuing through the variable region.

[0057] Antibodies, antigen-binding polypeptides, variants, or derivatives thereof of the disclosure include, but are not limited to, polyclonal, monoclonal, multi specific, human, humanized, primatized, or chimeric antibodies, single chain antibodies, epitope-binding fragments, e.g., Fab, Fab’ and F(ab’)2, Fd, Fvs, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv), fragments comprising either a VK or VH domain, fragmentsproduced by a Fab expression library, and anti- idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to LIGHT antibodies disclosed herein). Immunoglobulin or antibody molecules of the disclosure can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgGl, IgG2, IgG3, IgG4, IgAl and IgA2) or subclass of immunoglobulin molecule.

[0058] Light chains are classified as either kappa or lambda (K, ). Each heavy chain class may be bound with either a kappa or lambda light chain. In general, the light and heavy chains are covalently bonded to each other, and the “tail” portions of the two heavy chains are bonded to each other by covalent disulfide linkages or non-covalent linkages when the immunoglobulins are generated either by hybridomas, B cells or genetically engineered host cells. In the heavy chain, the amino acid sequences run from an N-terminus at the forked ends of the Y configuration to the C-terminus at the bottom of each chain.

[0059] Both the light and heavy chains are divided into regions of structural and functional homology. The terms “constant” and “variable” are used functionally. In this regard, it will be appreciated that the variable domains of both the light ( VK) and heavy (VH) chain portions determine antigen recognition and specificity. Conversely, the constant domains of the light chain (CK) and the heavy chain (CHI, CH2 or CH3) confer important biological properties such as secretion, transplacental mobility, Fc receptor binding, complement binding, and the like. By convention the numbering of the constant region domains increases as they become more distal from the antigen-binding site or amino- terminus of the antibody. The N-terminal portion is a variable region and at the C-terminal portion is a constant region; the CH3 and CK domains actually comprise the carboxy-terminus of the heavy and light chain, respectively.

[0060] As indicated above, the variable region allows the antibody to selectively recognize and specifically bind epitopes on antigens. That is, the VK domain and VH domain, or subset of the complementarity determining regions (CDRs), of an antibody combine to form the variable region that defines a three dimensional antigen-binding site. This quaternary antibody structure forms the antigen-binding site present at the end of each arm of the Y. More specifically, the antigen-binding site is defined by three CDRs on each of the VH and VK chains (i.e. CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2 and CDR-L3). In some instances, e.g., certain immunoglobulin molecules derived from camelid species or engineered based on camelid immunoglobulins, a complete immunoglobulin molecule may consist of heavy chains only, with no light chains. See, e.g., Hamers-Casterman et al., Nature 363:446-448 (1993).

[0061] In naturally occurring antibodies, the six “complementarity determining regions” or “CDRs” present in each antigen-binding domain are short, non-contiguous sequences of amino acids that are specifically positioned to form the antigen-binding domain as the antibody assumes its three dimensional configuration in an aqueous environment. The remainder of the amino acids in the antigen-binding domains, referred to as “framework” regions, show less inter- molecular variability. The framework regions largely adopt a P-sheet conformation and the CDRs form loops which connect, and in some cases form part of, the [3 -sheet structure. Thus, framework regions act to form a scaffold that provides for positioning the CDRs in correct orientation by inter-chain, non-covalent interactions. The antigen-binding domain formed by the positioned CDRs defines a surface complementary to the epitope on the immunoreactive antigen. This complementary surface promotes the non-covalent binding of the antibody to its cognate epitope. The amino acids comprising the CDRs and the framework regions, respectively, can be readily identified for any given heavy or light chain variable region by one of ordinary skill in the art, since they have been precisely defined see “Sequences of Proteins of Immunological Interest,” Kabat, E., et al., U.S. Department of Health and Human Services, (1983); and Chothia and Lesk, J. Mol. Biol., 196:901-917 (1987)).

[0062] In the case where there are two or more definitions of a term which is used and / or accepted within the art, the definition of the term as used herein is intended to include all such meanings unless explicitly stated to the contrary. A specific example is the use of the term “complementarity determining region” (“CDR”) to describe the non-contiguous antigen combining sites found within the variable region of both heavy and light chain polypeptides. This particular region has been described by Kabat et al., U.S. Dept, of Health and Human Services, “Sequences of Proteins of Immunological Interest” (1983) and by Chothia et al., J. Mol. Biol. 196:901-917 (1987), which are incorporated herein by reference in their entireties. The CDR definitions according to Kabat and Chothia include overlapping or subsets of amino acid residues when compared against each other. Nevertheless, application of either definition to refer to a CDR of an antibody or variants thereof is intended to be within the scope of the term as defined and used herein. The appropriate amino acid residues which encompass the CDRs as defined by each of the above cited references are set forth in the table below as a comparison. The exact residue numbers which encompass a particular CDR will vary depending on the sequence and size of the CDR. Those skilled in the art can routinelydetermine which residues comprise a particular CDR given the variable region amino acid sequence of the antibody.

[0063] As used herein, the term “CDR” or “complementarity determining region” is intended to mean the non-contiguous antigen combining sites found within the variable region of both heavy and light chain polypeptides. These particular regions have been described by Kabat et al., J. Biol. Chem. 252:6609-6616 (1977); Kabat et al., U.S. Dept, of Health and Human Services, “Sequences of proteins of immunological interest” (1991); Chothia et al., J. Mol. Biol.196:901-917 (1987); Al-Lazikani B. et al., J. Mol. Biol., 273: 927-948 (1997); MacCallum et al., J. Mol. Biol. 262:732-745 (1996); Abhinandan and Martin, Mol. Immunol., 45: 3832-3839 (2008); Lefranc M.P. et al., Dev. Comp. Immunol., Th -ll (2003); and Honegger and Pluckthun, J. Mol. Biol., 309:657-670 (2001), where the definitions include overlapping or subsets of amino acid residues when compared against each other. Nevertheless, application of either definition to refer to a CDR of an antibody or grafted antibodies or variants thereof is intended to be within the scope of the term as defined and used herein. The amino acid residues which encompass the CDRs as defined by each of the above cited references are set forth below in Table 1 as a comparison. CDR prediction algorithms and interfaces arc known in the art, including, for example, Abhinandan and Martin, Mol. Immunol., 45: 3832-3839 (2008);Ehrenmann F. et al.. Nucleic Acids Res., 38: D301-D307 (2010); and Adolf-Bryfogle J. et al., Nucleic Acids Res., 43: D432-D438 (2015). The contents of the references cited in this paragraph are incorporated herein by reference in their entireties for use in the present application and for possible inclusion in one or more claims herein.Table 1. CDR DefinitionsKabat1Chothia2MacCallum1IMGT4AHo5VH CDR1 31-35 26-32 30-35 27-38 25-40 VH CDR2 50-65 53-55 47-58 56-65 58-77 VH CDR3 95-102 96-101 93-101 105-117 109-137 VL CDR1 24-34 26-32 30-36 27-38 25-40 VL CDR2 50-56 50-52 46-55 56-65 58-77VL CDR3 89-97 91-96 89-96 105-117 109-137 'Residue numbering follows the nomenclature of Kabat et al., supra2Residue numbering follows the nomenclature of Chothia et al., supra3Residue numbering follows the nomenclature of MacCallum et al., supra4Residue numbering follows the nomenclature of Lefranc et al., supra5Residue numbering follows the nomenclature of Honegger and Pluckthun, supra

[0064] The expression “variable-domain residue-numbering as in Kabat’’ or “amino-acid-position numbering as in Kabat,’’ and variations thereof, refers to the numbering system used for heavy-chain variable domains or light-chain variable domains of the compilation of antibodies in Kabat et al., supra. Using this numbering system, the actual linear amino acid sequence may contain fewer or additional amino acids corresponding to a shortening of, or insertion into, a FR or hypervariable region (HVR) of the variable domain. For example, a heavy-chain variable domain may include a single amino acid insert (residue 52a according to Kabat) after residue 52 of H2 and inserted residues (e.g. residues 82a, 82b, and 82c, etc. according to Kabat) after heavy-chain FR residue 82. The Kabat numbering of residues may be determined for a given antibody by alignment at regions of homology of the sequence of the antibody with a “standard" Kabat numbered sequence.

[0065] Unless indicated otherwise herein, the numbering of the residues in an immunoglobulin heavy chain is that of the EU index as in Kabat et al., supra with minor modification. The “EU index as in Kabat” refers to the residue numbering of the human IgG EU antibody.

[0066] “Framework" or “FR” residues are those variable-domain residues other than the CDR residues as herein defined.

[0067] Antibodies disclosed herein may be from any animal origin including birds and mammals. Preferably, the antibodies are human, murine, donkey, rabbit, goat, guinea pig, camel, llama, horse, or chicken antibodies. In another embodiment, the variable region may be condricthoid in origin (e.g., from sharks).

[0068] As used herein, the term “chimeric antibody” will be held to mean any antibody wherein the immunoreactive region or site is obtained or derived from a first species and the constant region (which may be intact, partial or modified in accordance with the instant disclosure) is obtained from a second species. In certain embodiments the target binding region or site will be from a non-human source (e.g. mouse or primate) and the constant region is human.

[0069] "Humanized antibody" is used herein to describe an antibody that comprises heavy and light chain variable region sequences from a non-human species (e.g. a mouse) but in which at least a portion of the VH and / or VL sequence has been altered to be more "human- like," i.e., more similar to human germline variable sequences. A "humanized antibody" is an antibody or a variant, derivative, analog, or fragment thereof, which immunospecifically binds to an antigen of interest and which comprises a framework (FR) region having substantially the amino acidsequence of a human antibody and a complementary determining region (CDR) having substantially the amino acid sequence of a non-human antibody. As used herein, the term "substantially" in the context of a CDR refers to a CDR having an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identical to the amino acid sequence of a non-human antibody CDR. A humanized antibody comprises substantially all of at least one, and typically two, variable domains (Fab, Fab', F(ab')2, Fv) in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin (i.e., donor antibody) and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. In an embodiment, a humanized antibody also comprises at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. In some embodiments, a humanized antibody contains the light chain as well as at least the variable domain of a heavy chain. The antibody also may include the CHI, hinge, CH2, CH3, and CH4 regions of the heavy chain. In some embodiments, a humanized antibody only contains a humanized light chain. In some embodiments, a humanized antibody only contains a humanized heavy chain. In specific embodiments, a humanized antibody only contains a humanized variable domain of a light chain and / or humanized heavy chain.

[0070] As used herein, the term “VH domain” includes the amino terminal variable domain of an immunoglobulin heavy chain, and the term “VL domain” includes the amino terminal variable domain of an immunoglobulin light chain.

[0071] As used herein, the term “heavy chain constant region” includes amino acid sequences derived from an immunoglobulin heavy chain. A polypeptide comprising a heavy chain constant region comprises at least one of: a CHI domain, a hinge (e.g., upper, middle, and / or lower hinge region) domain, a CH2 domain, a CH3 domain, or a variant or fragment thereof. For example, an antigen-binding polypeptide for use in the disclosure may comprise a polypeptide chain comprising a CHI domain; a polypeptide chain comprising a CHI domain, at least a portion of a hinge domain, and a CH2 domain; a polypeptide chain comprising a CHI domain and a CH3 domain; a polypeptide chain comprising a CHI domain, at least a portion of a hinge domain, and a CH3 domain, or a polypeptide chain comprising a CHI domain, at least a portion of a hinge domain, a CH2 domain, and a CH3 domain. In another embodiment, a polypeptide of the disclosure comprises a polypeptide chain comprising a CH3 domain.Further, an antibody for use in the disclosure may lack at least a portion of a CH2 domain e.g.,all or part of a CH2 domain). As set forth above, it will be understood by one of ordinary skill in the art that the heavy chain constant region may be modified such that they vary in amino acid sequence from the naturally occurring immunoglobulin molecule.

[0072] The heavy chain constant region of an antibody disclosed herein may be derived from different immunoglobulin molecules. For example, a heavy chain constant region of a polypeptide may comprise a CHI domain derived from an IgGi molecule and a hinge region derived from an IgGj molecule. In another example, a heavy chain constant region can comprise a hinge region derived, in part, from an IgGi molecule and, in part, from an IgG molecule. In another example, a heavy chain portion can comprise a chimeric hinge derived, in part, from an IgGi molecule and, in part, from an IgG4 molecule.

[0073] As used herein, the term “light chain constant region” includes amino acid sequences derived from antibody light chain. Preferably, the light chain constant region comprises at least one of a constant kappa domain or constant lambda domain.

[0074] A “light chain-heavy chain pair” refers to the collection of a light chain and heavy chain that can form a dimer through a disulfide bond between the CL domain of the light chain and the CHI domain of the heavy chain.

[0075] As previously indicated, the subunit structures and three dimensional configuration of the constant regions of the various immunoglobulin classes are well known. As used herein, the term “VH domain” includes the amino terminal variable domain of an immunoglobulin heavy chain and the term “CHI domain” includes the first (most amino terminal) constant region domain of an immunoglobulin heavy chain. The CHI domain is adjacent to the VH domain and is amino terminal to the hinge region of an immunoglobulin heavy chain molecule.

[0076] The “CHI domain” (also referred to as “Cl” of “Hl” domain) usually extends from about amino acid 118 to about amino acid 215 (EU index as in Kabat).

[0077] “Hinge region” is generally defined as a region in IgG corresponding to Glu216 to Pro230 of human IgGi (Burton, Molec. Immunol.22A6 -206 (1985)). Hinge regions of other IgG isotypes may be aligned with the IgGi sequence by placing the first and last cysteine residues forming inter-heavy chain S-S bonds in the same positions.

[0078] The “CH2 domain” of a human IgG Fc region (also referred to as “C2” domain) usually extends from about amino acid 231 to about amino acid 340. The CH2 domain is unique in that it is not closely paired with another domain. Rather, two N-linked branched carbohydrate chainsare interposed between the two CH2 domains of an intact native IgG molecule. It has been speculated that the carbohydrate may provide a substitute for the domain-domain pairing and help stabilize the CH2 domain. Burton, Molec Immunol. 22:161-206 (1985).

[0079] The “CH3 domain” (also referred to as “C3” domain) comprises the stretch of residues C-terminal to a CH2 domain in an Fc region (i.e. from about amino acid residue 341 to the C-terminal end of an antibody sequence, typically at amino acid residue 446 or 447 of an IgG).

[0080] By ‘ ‘Fc”, “Fc domain” or “Fc region”, as used herein is meant the polypeptide comprising the constant region of an antibody excluding the first constant region immunoglobulin domain. Thus Fc refers to the last two constant region immunoglobulin domains of IgA, IgD, and IgG, the last three constant region immunoglobulin domains of IgE and IgM, and the flexible hinge N-terminal to these domains. For IgA and IgM, Fc may include the I chain. For IgG, Fc comprises immunoglobulin domains Cgamma2 and Cgamma3 (Cy2 and Cy3 which arc CH2 and CH3 domains, respectively for IgGs) and the lower hinge region between Cgammal (Cyl) and Cgamma2 (Cy2). The human IgGl heavy chain Fc region is defined herein to comprise residues C226 to its carboxyl-terminus, wherein the numbering is according to the EU index as in Kabat. In the context of human IgGl, the lower hinge refers to positions 226-236, the CH2 domain refers to positions 237-340 and the CH3 domain refers to positions 341-447 according to the EU index as in Kabat. The corresponding Fc region of other immunoglobulins can be identified by sequence alignments.

[0081] The original immunoglobulin source of the native Fc is typically of human origin and can be any of the immunoglobulins, such as IgGl and lgG2. Native Fc molecules are made up of monomeric polypeptides that can be linked into dimeric or multimeric forms by covalent (i.e., disulfide bonds) and non-covalent association. The number of intermolecular disulfide bonds between monomeric subunits of native Fc molecules ranges from 1 to 4 depending on class (e.g., IgG, IgA, and IgE) or subclass (e.g., IgGl, IgG2, IgG3 and IgG4). In mice, IgG comprises IgGl, IgG2a, IgG2b, IgG3. Full-length IgGs are tetramers and consist of two identical pairs of two immunoglobulin chains, each pair having one light and one heavy chain, each light chain comprising immunoglobulin domains VL and CL, and each heavy chain comprising immunoglobulin domains VH, Cyl (also called CHI), Cy2 (also called CH2), and Cy3 (also called CH3). One example of a native Fc is a disulfide-bonded dimer resulting from papain digestion of an IgG. The term “native Fc,” as used herein, is generic to the monomeric, dimeric, and multimeric forms.

[0082] The term “Fc variant,” “modified Fc,” or “modified Fc domain,” as used herein, refers to a molecule or sequence that is modified from a native / wildtype Fc but still includes binding site for the FcRn. A Fc variant or a modified Fc domain also can be shorter or longer than a native Fc (e.g., shorter or longer than a sequence spanning residues 216 to 447 of human IgG, EU index as in Kabat); for example, the Fc variant or modified Fc may lack certain N-terminal and / or C-terminal amino acid residues of the native Fc, or may contain additional amino acid residues at the N-terminus and / or C-terminus compared to a native Fc. A modified Fc domain itself does not include an antigen-binding domain of an antibody or an antibody variant, or a target-binding domain of an immunoadhesin, but the modified Fc domain or the fusion protein described herein can be linked to such a domain to form an modified Fc domain that binds also to a non-FcRn target. The term encompasses a molecule or sequence that is humanized from a non-human native Fc. Furthermore, a native Fc comprises regions that can be removed because they provide structural features or biological activities that are not required for the modified Fc domain or the fusion protein described herein (e.g., antibody-like binding polypeptides) described herein. Thus, the term encompasses a molecule or sequence that lacks one or more native Fc sites or residues, or in which one or more Fc sites or residues have been modified, that affect or are involved in: (1) disulfide bond formation, (2) incompatibility with a selected host cell, (3)N-terminal heterogeneity upon expression in a selected host cell, (4) glycosylation, (5) interaction with complement, (6) binding to an Fc receptor other than a salvage receptor (an FcyR), or (7) antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).

[0083] “Effector functions” or “antibody effector functions” as used herein refer to biological activities attributable to the binding of Fc region of an antibody to its effectors such as C 1 complex and Fc receptor (FcyRIIa or FcyRIIIa). Exemplary effector functions include: complement dependent cytotoxicity (CDC) induced by interaction of antibodies and Clq on the Cl complex; antibody-dependent cell-mediated cytotoxicity (ADCC) induced by binding of Fc region of an antibody to Fc receptor on an effector cell; and antibody dependent cell mediated phagocytosis (ADCP) , where nonspecific cytotoxic cells that express Fey receptors (FcyRs) recognize bound antibody on a target cell and subsequently cause phagocytosis of the target cell.

[0084] “Fc receptor” or “FcR” describes a receptor that binds the Fc region of an antibody. The preferred FcR is a native sequence human FcR. Moreover, a preferred FcR is one which bindsan IgG antibody (a gamma receptor) and includes receptors of the FcyRI, FcyRII, and FcyRIII subclasses, including allelic variants and alternatively spliced forms of these receptors, FcyRII receptors include FcyRIIA (an “activating receptor”) and FcyRIIB (an “inhibiting receptor”), which have similar amino acid sequences that differ primarily in the cytoplasmic domains thereof. Activating receptor FcyRIIA contains an immunoreceptor tyrosine-based activation motif (IT AM) in its cytoplasmic domain. Inhibiting receptor FcyRIIB contains an immunoreceptor tyrosine-based inhibition motif (ITIM) in its cytoplasmic domain. (See M. Daeron, Annu. Rev. Immunol. 15:203-234 (1997). FcRs are reviewed in Ravetch and Kinet, Annu. Rev. Immunol. 9: 457-92 (1991); Capel et al., Immunomethods 4: 25-34 (1994); and de Haas et al., J. Lab. Clin. Med. 126: 330-41 (1995). Other FcRs, including those to be identified in the future, are encompassed by the term “FcR” herein.

[0085] Unless otherwise specified, the percent sequence identity between two amino acid sequences is determined by globally aligning them using the Needleman-Wunsch algorithm with affine gap penalties, the BLOSUM62 substitution matrix, a gap open penalty of -11, and a gap extension penalty of-1, where a gap of length / has total cost -11 + (k-l)x(-l). Both sequences arc aligned in their entirety, with no free end gaps. When multiple alignments achieve the same optimal score, ties are broken by preferring match / mismatch states over gap states, and preferring to open a new gap over extending an existing one. The number of alignment positions where both sequences have the same amino acid (identities), divided by the total number of positions in the alignment (including all gap positions), multiplied by 100, gives the percent sequence identity. This alignment can be produced using the pairwiseAlignmentQ function in the pwalign package (available through the Bioconductor project for the R programming language), with the type parameter set to "global," the substitutionMatrix parameter set to "BLOSUM62," the gapOpening parameter set to -10, and the gapExtension parameter set to -1. (In the pwalign convention, the total cost of the first position in a gap is the sum of the gapOpening and gapExtension parameters (-10 + (-1) = -11), which corresponds to the gap open penalty of -11 described above.) The percent sequence identity can then be obtained by dividing the number of identical positions in the alignment by the total number of positions in the alignment, expressed as a percentage (i.e., identical positions + nchar(alignedPattem) x 100).

[0086] In an alternative embodiment, % amino acid sequence identity values are generated using the sequence comparison computer program MUSCLE (Edgar, R.C., Nucleic Acids Research 32(5): 1792-1797, 2004; Edgar, R.C., BMC Bioinformatics 5(1): 113, 2004).

[0087] By “specifically binds” or “has specificity to,” it is generally meant that an antibody binds to an epitope via its antigen-binding domain, and that the binding entails some complementarity between the antigen-binding domain and the epitope. According to this definition, an antibody is said to “specifically bind” to an epitope when it binds to that epitope, via its antigen-binding domain more readily than it would bind to a random, unrelated epitope. The term “specificity” is used herein to qualify the relative affinity by which a certain antibody binds to a certain epitope. For example, antibody “A” may be deemed to have a higher specificity for a given epitope than antibody “B,” or antibody “A” may be said to bind to epitope “C” with a higher specificity than it has for related epitope “D.”

[0088] An “isolated” polypeptide (or construct) or cell is one that has been identified, separated and / or recovered from a component of its production environment (e.g., natural or recombinant). Preferably, the isolated polypeptide or cell is free of association with all other components from its production environment.

[0089] An “isolated” nucleic acid molecule encoding a construct, polypeptide, antibody, or antigen-binding fragment thereof described herein is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the environment in which it was produced. Preferably, the isolated nucleic acid is free of association with all components associated with the production environment. The isolated nucleic acid molecules encoding the polypeptides and antibodies described herein is in a form other than in the form or setting in which it is found in nature. Isolated nucleic acid molecules therefore are distinguished from nucleic acid encoding the polypeptides and antibodies described herein existing naturally in cells. An isolated nucleic acid includes a nucleic acid molecule contained in cells that ordinarily contain the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.

[0090] Nucleic acid is “operably linked” when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates inthe secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, “operably linked” means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading frame. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.

[0091] The term “transfected” or “transformed” or “transduced” as used herein refers to a process by which exogenous nucleic acid is transferred or introduced into the host cell. A “transfected” or “transformed” or “transduced” cell is one which has been transfected, transformed or transduced with exogenous nucleic acid. The cell includes the primary subject cell and its progeny.

[0092] The terms “host cell,” “host cell line,” and “host cell culture” arc used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include “transformants” and “transformed cells,” which include the primary transformed cell and progeny derived therefrom without regard to the number of passages. Progeny may not be completely identical in nucleic acid content to a parent cell, and may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein.

[0093] As used herein, the terms “treat” or “treatment” refer to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) an undesired physiological change or disorder, such as the progression of cancer. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (z.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. “Treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already with the condition or disorder as well as those prone to have the condition or disorder or those in which the condition or disorder is to be prevented.

[0094] By “subject” or “individual” or “animal” or “patient” or “mammal,” is meant any subject, particularly a mammalian subject, for whom diagnosis, prognosis, or therapy is desired.Mammalian subjects include humans, domestic animals, farm animals, and zoo, sport, or pet animals such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, cows, and so on.

[0095] As used herein, phrases such as “to a patient in need of treatment” or “a subject in need of treatment” includes subjects, such as mammalian subjects, that would benefit from administration of an antibody or composition of the present disclosure used, e.g., for detection, for a diagnostic procedure and / or for treatment.Modified Fc Domains

[0096] Provided herein is a modified Fc domain with particular mutations and modifications. In certain embodiments, the modified Fc domain or the Fc domain of the fusion protein described herein is derived from a human IgGl Fc domain. In certain embodiments, the modified Fc domain or the Fc domain of the fusion protein described herein is derived from a human IgG2 Fc domain. In certain embodiments, the modified Fc domain or the Fc domain of the fusion protein described herein is derived from a human IgG3 Fc domain. In certain embodiments, the modified Fc domain or the Fc domain of the fusion protein described herein is derived from a human IgG4 Fc domain.

[0097] Fc domains from any IgG subtype can be used to generate an FcRn and / or FcyRIIB binding domain of the present disclosure. In some embodiments, the modified Fc domain is derived from a human IgGl, IgG2, IgG3, or IgG4 Fc domain and comprises the substitutions described herein relative to the wildtype origin. In certain other embodiments, the modified Fc domain is an artificial Fc derived from more than one IgG subtype. In some embodiments, the Fc domains comprise a chimeric hinge (i.e., a hinge comprising hinge portions derived from hinge domains of different antibody isotypes, e.g., an upper hinge domain from an IgG4 molecule and an IgGl middle hinge domain).

[0098] Human IgGl naturally binds FcRn at an acidic pH, which allows it to, upon binding FcRn and internalization into a cell, be recycled back to the surface of the cell and not to be degraded in the lysosome. In some embodiments, Fc domain mutations are introduced to increase the binding of the Fc domains to human FcRn at acidic pH and / or neutral pH.Mutations that increase binding of the Fc domains to FcRn in neutral pH environments may be included in the molecules described herein in order to increase binding of the Fc domain to FcRn on the surface of a cell at a neutral pH, such that there will be increased receptor-mediated internalization into cells and shuttling of the antigens, autoantibodies or autoantigens(bound to the molecule) to the lysosome. In certain embodiments, the modified Fc domain provided herein is pH-independent. In certain embodiments, the modified Fc domain provided herein binds to FcRn of different species, such as human FcRn, mouse FcRn, rat FcRn, rabbit FcRn and / or cyno FcRn.

[0099] According to one aspect, provided herein is a modified Fc domain including modifications to enhance binding to FcRn (e.g., human FcRn). In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) at position(s) 252, 254, 256, 308, 433, or 434. In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, M252W, S254T, T256E, V308P, H433K, H433R, N434Y, N434F, and N434W. In some embodiments, the modified Fc domain includes two or more amino acid substitution(s) selected from the group consisting of M252Y, M252W, S254T, T256E, V308P, H433K, H433R, N434Y, N434F, and N434W. In some embodiments, the modified Fc domain includes three or more amino acid substitution(s) selected from the group consisting of M252Y, M252W, S254T, T256E, V308P, H433K, H433R, N434Y, N434F, and N434W. In some embodiments, the modified Fc domain includes four or more amino acid substitution(s) selected from the group consisting of M252Y, M252W, S254T, T256E, V308P, H433K, H433R, N434Y, N434F, and N434W. In some embodiments, the modified Fc domain includes five or more amino acid substitution(s) selected from the group consisting of M252Y, M252W, S254T, T256E, V308P, H433K, H433R, N434Y, N434F, and N434W. In some embodiments, the modified Fc domain includes six or more amino acid substitution(s) selected from the group consisting of M252Y, M252W, S254T, T256E, V308P, H433K, H433R, N434Y, N434F, and N434W.

[0100] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, V308P, and N434Y. In some embodiments, the modified Fc domain includes two or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, V308P, and N434Y. In some embodiments, the modified Fc domain includes three or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, V308P, and N434Y. In some embodiments, the modified Fc domain includes four or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, V308P, and N434Y. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / V308P / N434Y (“YTEPY”).

[0101] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, H433K, and N434F. In some embodiments, the modified Fc domain includes two or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, H433K, and N434F. In some embodiments, the modified Fc domain includes three or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, H433K, and N434F. In some embodiments, the modified Fc domain includes four or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, H433K, and N434F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252 Y / S254T / T256E / H433 K / N434F (“YTEKF”) .

[0102] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, and T256E. In some embodiments, the modified Fc domain includes two or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, and T256E. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E ("YTE").

[0103] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, and N434W. In some embodiments, the modified Fc domain includes two or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, and N434W. In some embodiments, the modified Fc domain includes three or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, and N434W. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / N434W ("YTEW").

[0104] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, V308P, and N434Y. In some embodiments, the modified Fc domain includes two or more amino acid substitution(s) selected from the group consisting of M252Y, V308P, and N434Y. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / V308P / N434Y ("YPY").

[0105] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, V308P, and N434F. In some embodiments, the modified Fc domain includes two or more amino acidsubstitution(s) selected from the group consisting of M252Y, S254T, T256E, V308P, and N434F. In some embodiments, the modified Fc domain includes three or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, V308P, and N434F. In some embodiments, the modified Fc domain includes four or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, V308P, and N434F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / V308P / N434F ("YTEPF").

[0106] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, V308P, H433R, and N434Y. In some embodiments, the modified Fc domain includes two or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, V308P, H433R, and N434Y. In some embodiments, the modified Fc domain includes three or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, V308P, H433R, and N434Y. In some embodiments, the modified Fc domain includes four or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, V308P, H433R, and N434Y. In some embodiments, the modified Fc domain includes five or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, V308P, H433R, and N434Y. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / V308P / H433R / N434Y ("YTEPRY").

[0107] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252W, V308P, H433R, and N434Y. In some embodiments, the modified Fc domain includes two or more amino acid substitution(s) selected from the group consisting of M252W, V308P, H433R, and N434Y. In some embodiments, the modified Fc domain includes three or more amino acid substitution(s) selected from the group consisting of M252W, V308P, H433R, and N434Y. In some embodiments, the modified Fc domain includes amino acid substitutions of M252W / V308P / H433R / N434Y ("WPRY").

[0108] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252W, V308P, and N434F. In some embodiments, the modified Fc domain includes two or more amino acid substitution(s) selected from the group consisting of M252W, V308P, and N434F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252W / V308P / N434F ("WPF").

[0109] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252W and N434W. In some embodiments, the modified Fc domain includes amino acid substitutions of M252W / N434W ("WW").

[0110] In some embodiments, Fc domain mutations can be introduced to increase binding of the Fc domains to human FcyRIIB. Such mutations allow for binding to FcyRIIB at neutral pH. Upon binding, the molecule / antigen, autoantibody, or autoantigen complex may be internalized into the cell and targeted to the lysosome for degradation. In certain embodiments, the modified Fc domain can induce cross-linking between the BCR and FcyRIIB, thereby triggering selective inhibition or deletion of autoantibody- or autoantigen -producing B cells. In certain embodiments, the modified Fc domain provided herein binds to FcyRIIB of different species, such as human FcyRIIB, mouse FcyRIIB, rat FcyRIIB, rabbit FcyRIIB and / or cyno FcyRIIB.

[0111] According to one aspect, provided herein is a modified Fc domain including modifications to enhance binding to FcyRIIB (e.g., human FcyRIIB). In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) at position(s) 236, 237, 238, 267, or 328. In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of G236D, G237D, P238D, S267E, and L328F. In some embodiments, the modified Fc domain includes two or more amino acid substitution(s) selected from the group consisting of G236D, G237D, P238D, S267E, and L328F. In some embodiments, the modified Fc domain includes three or more amino acid substitution(s) selected from the group consisting of G236D, G237D, P238D, S267E, and L328F. In some embodiments, the modified Fc domain includes four or more amino acid substitution(s) selected from the group consisting of G236D, G237D, P238D, S267E, and L328F. In some embodiments, the modified Fc domain includes an amino acid deletion of AG236.

[0112] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of S267E and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of S267E / L328F ("SELF").

[0113] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of G236D and S267E. In some embodiments, the modified Fc domain includes amino acid substitutions of G236D / S267E ("DE").

[0114] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of G236D and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of G236D / L328F ("GDLF").

[0115] In some embodiments, the modified Fc domain includes one or more amino acid mutation(s) selected from the group consisting of AG236 and S267E. In some embodiments, the modified Fc domain includes an amino acid deletion of AG236 and an amino acid substitution of S267E ("AGSE").

[0116] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of G237D, P238D, and L328F. In some embodiments, the modified Fc domain includes two or more amino acid substitution(s) selected from the group consisting of G237D, P238D, and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of G237D / P238D / L328F ("GDPDLF").

[0117] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of G236D, G237D, P238D, and L328F. In some embodiments, the modified Fc domain includes two or more amino acid substitution(s) selected from the group consisting of G236D, G237D, P238D, and L328F. In some embodiments, the modified Fc domain includes three or more amino acid substitution(s) selected from the group consisting of G236D, G237D, P238D, and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of G236D / G237D / P238D / L328F ("GDGDPDLF").

[0118] In some embodiments, the modified Fc domain includes both modifications to increase the binding of the Fc domains to human FcRn and modifications to increase binding of the Fc domains to human FcyRIIB, such that the binding to both human FcRn and human FcyRIIB. The inventors of the present application has discovered that modifications to increase the binding of the Fc domains to human FcRn and modifications to increase binding of the Fc domains to human FcyRIIB show synergistic effect on increasing in internalization ability of Fc domains and fusion protein including such modifications.

[0119] For example, the modified Fc domain may include one or more amino acid substitution(s) at position(s) 252, 254, 256, 308, 433, or 434 and one or more amino acid substitution(s) at position(s) 236, 237, 238, 267, or 328. In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting ofM252Y, M252W, S254T, T256E, V308P, H433K, H433R, N434Y, N434F, and N434W, and one or more amino acid substitution(s) selected from the group consisting of G236D, G237D, P238D, S267E, and L328F.

[0120] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, V308P, and N434Y, and one or more amino acid substitution(s) selected from the group consisting of S267E and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / V308P / N434Y (“YTEPY”) and S267E / L328F ("SELF").

[0121] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, V308P, and N434Y, and one or more amino acid substitution(s) selected from the group consisting of G236D and S267E. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / V308P / N434Y ("YTEPY") and G236D / S267E ("DE").

[0122] In some embodiments, the modified Fc domain includes one or more amino acid mutation(s) selected from the group consisting of M252Y, S254T, T256E, V308P, and N434Y, and one or more amino acid modification(s) selected from the group consisting of AG236 and S267E. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / V308P / N434Y ("YTEPY"), an amino acid modification of AG236, and an amino acid substitution of S267E ("AGSE").

[0123] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, V308P, and N434Y, and one or more amino acid substitution(s) selected from the group consisting of G237D, P238D, and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / V308P / N434Y ("YTEPY") and G237D / P238D / L328F ("GDPDLF").

[0124] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, H433K, and N434F, and one or more amino acid substitution(s) selected from the group consisting of S267E and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / II433K / N434F ("YTEKF") and S267E / L328F ("SELF").

[0125] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, and T256E, and one or more amino acid substitution(s) selected from the group consisting of S267E and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E ("YTE") and S267E / L328F ("SELF").

[0126] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, and N434W, and one or more amino acid substitulion(s) selected from the group consisting of S267E and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / N434W ("YTEW") and S267E / E328F ("SELF").

[0127] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, V308P, and N434Y, and one or more amino acid substitution(s) selected from the group consisting of S267E and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / V308P / N434Y ("YPY") and S267E / L328F ("SELF").

[0128] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, V308P, and N434F, and one or more amino acid substitution(s) selected from the group consisting of S267E and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / V308P / N434F ("YTEPF") and S267E / L328F ("SELF").

[0129] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, V308P, H433R, and N434Y, and one or more amino acid substitution(s) selected from the group consisting of S267E and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / V308P / H433R / N434Y ("YTEPRY") and S267E / L328F ("SELF").

[0130] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252W, V308P, H433R, and N434Y, and one or more amino acid substitution(s) selected from the group consisting of S267E and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252W / V308P / II433R / N434Y ("WPRY") and S267E / L328F ("SELF").

[0131] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252W, V308P, and N434F, and one or more amino acid substitution(s) selected from the group consisting of S267E and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252W / V308P / N434F ("WPF") and S267E / L328F ("SELF").

[0132] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252W and N434W, and one or more amino acid substitution(s) selected from the group consisting of S267E and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252W / N434W ("WW") and S267E / L328F ("SELF").

[0133] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, and N434W, and one or more amino acid substitution(s) selected from the group consisting of G236D and S267E. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / N434W ("YTEW") and G236D / S267E ("DE").

[0134] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252W, V308P, and N434F, and one or more amino acid substitution(s) selected from the group consisting of G236D and S267E. In some embodiments, the modified Fc domain includes amino acid substitutions of M252W / V308P / N434F ("WPF") and G236D / S267E ("DE").

[0135] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, V308P, and N434Y, and one or more amino acid substitution(s) selected from the group consisting of G236D and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / V308P / N434Y ("YTEPY") and G236D / L328F ("GDLF").

[0136] In some embodiments, the modified Fc domain includes one or more amino acid mutation(s) selected from the group consisting of M252Y, S254T, T256E, V308P, and N434Y, and one or more amino acid modification(s) selected from the group consisting of AG236 and S267E. In some embodiments, the modified Fc domain includes amino acid substitutions ofM252Y / S254T / T256E / V308P / N434Y ("YTEPY"), an amino add deletion of AG236, and an amino acid substitution of S267E ("AGSE").

[0137] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, and N434W, and one or more amino acid substitution(s) selected from the group consisting of G237D, P238D, and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / N434W ("YTEW") and G237D / P238D / L328F ("GDPDLF").

[0138] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, and N434W, and one or more amino acid substitution(s) selected from the group consisting of G236D, G237D, P238D, and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / N434W ("YTEW") and G236D / G237D / P238D / L328F ("GDGDPDLF").

[0139] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, V308P, and N434Y, and one or more amino acid substitution(s) selected from the group consisting of G236D, G237D, P238D, and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / V308P / N434Y ("YTEPY") and G236D / G237D / P238D / L328F ("GDGDPDLF").

[0140] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, H433K, and N434F, and one or more amino acid substitution(s) selected from the group consisting of G236D and S267E. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / H433K / N434F ("YTEKF") and G236D / S267E ("DE").

[0141] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, H433K, and N434F, and one or more amino acid substitution(s) selected from the group consisting of G236D and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / H433K / N434F ("YTEKF") and G236D / L328F("GDLF").

[0142] In some embodiments, the modified Fc domain includes one or more amino acid mutation(s) selected from the group consisting of M252Y, S254T, T256E, H433K, and N434F, and one or more amino acid modification(s) selected from the group consisting of AG236 and S267E. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / H433K / N434F ("YTEKF"), an amino acid deletion of AG236, and an amino acid substitution of S267E ("AGSE").

[0143] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, H433K, and N434F, and one or more amino acid substitution(s) selected from the group consisting of G237D, P238D, and E328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / H433K / N434F ("YTEKF") and G237D / P238D / L328F ("GDPDLF").

[0144] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, H433K, and N434F, and one or more amino acid substitution(s) selected from the group consisting of G236D, G237D, P238D, and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / H433K / N434F ("YTEKF") and G236D / G237D / P238D / L328F ("GDGDPDLF").

[0145] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, and T256E, and one or more amino acid substitution(s) selected from the group consisting of G236D and S267E. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E ("YTE") and G236D / S267E ("DE").

[0146] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, and T256E, and one or more amino acid substitution(s) selected from the group consisting of G236D and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E ("YTE") and G236D / L328F ("GDLF").

[0147] In some embodiments, the modified Fc domain includes one or more amino acid mutation(s) selected from the group consisting of M252Y, S254T, and T256E, and one or more amino acid modification(s) selected from the group consisting of AG236 and S267E. In someembodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E ("YTE"), an amino acid deletion of AG236, and an amino acid substitution of S267E ("AGSE").

[0148] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, and T256E, and one or more amino acid substitution(s) selected from the group consisting of G237D, P238D, and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E ("YTE") and G237D / P238D / L328F ("GDPDLF").

[0149] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, and T256E, and one or more amino acid substitution(s) selected from the group consisting of G236D, G237D, P238D, and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E ("YTE") and G236D / G237D / P238D / L328F ("GDGDPDLF").

[0150] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, and N434W, and one or more amino acid substitution(s) selected from the group consisting of G236D and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / N434W ("YTEW") and G236D / L328F ("GDLF").

[0151] In some embodiments, the modified Fc domain includes one or more amino acid mutation(s) selected from the group consisting of M252Y, S254T, T256E, and N434W, and one or more amino acid modification(s) selected from the group consisting of AG236 and S267E. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / N434W ("YTEW"), an amino acid deletion of AG236, and an amino acid substitution of S267E ("AGSE").

[0152] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, V308P, and N434Y, and one or more amino acid substitution(s) selected from the group consisting of G236D and S267E. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / V308P / N434Y ("YPY") and G236D / S267E ("DE").

[0153] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, V308P, and N434Y, and one ormore amino acid substitution(s) selected from the group consisting of G236D and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / V308P / N434Y ("YPY") and G236D / L328F ("GDLF").

[0154] In some embodiments, the modified Fc domain includes one or more amino acid mutation(s) selected from the group consisting of M252Y, V308P, and N434Y, and one or more amino acid mutation(s) selected from the group consisting of AG236 and S267E. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / V308P / N434Y ("YPY"), an amino acid deletion of AG236, and an amino acid substitution of S267E ("AGSE").

[0155] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, V308P, and N434Y, and one or more amino acid substitution(s) selected from the group consisting of G237D, P238D, and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / V308P / N434Y ("YPY") and G237D / P238D / L328F ("GDPDLF").

[0156] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, V308P, and N434Y, and one or more amino acid substitution(s) selected from the group consisting of G236D, G237D, P238D, and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / V308P / N434Y ("YPY") and G236D / G237D / P238D / L328F ("GDGDPDLF").

[0157] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, V308P, and N434F, and one or more amino acid substitution(s) selected from the group consisting of G236D and S267E. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / V308P / N434F ("YTEPF") and G236D / S267E ("DE").

[0158] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, V308P, and N434F, and one or more amino acid substitution(s) selected from the group consisting of G236D and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / V308P / N434F ("YTEPF") and G236D / L328F("GDLF").

[0159] In some embodiments, the modified Fc domain includes one or more amino acid mutation(s) selected from the group consisting of M252Y, S254T, T256E, V308P, and N434F, and one or more amino acid modification(s) selected from the group consisting of AG236 and S267E. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / V308P / N434F ("YTEPF"), an amino acid deletion of AG236, and an amino acid substitution of S267E ("AGSE").

[0160] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, V308P, and N434F, and one or more amino acid substitution(s) selected from the group consisting of G237D, P238D, and E328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / V308P / N434F ("YTEPF") and G237D / P238D / L328F ("GDPDLF").

[0161] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, V308P, and N434F, and one or more amino acid substitution(s) selected from the group consisting of G236D, G237D, P238D, and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / V308P / N434F ("YTEPF") and G236D / G237D / P238D / L328F ("GDGDPDLF").

[0162] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, V308P, H433R, and N434Y, and one or more amino acid substitution(s) selected from the group consisting of G236D and S267E. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / V308P / H433R / N434Y ("YTEPRY") and G236D / S267E ("DE").

[0163] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, V308P, H433R, and N434Y, and one or more amino acid substitution(s) selected from the group consisting of G236D and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / V308P / H433R / N434Y ("YTEPRY") and G236D / L328F ("GDLF").

[0164] In some embodiments, the modified Fc domain includes one or more amino acid mutation(s) selected from the group consisting of M252Y, S254T, T256E, V308P, H433R, and N434Y, and one or more amino acid modification(s) selected from the group consisting of AG236 and S267E. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / V308P / H433R / N434Y ("YTEPRY"), an amino acid deletion of AG236, and an amino acid substitution of S267E ("AGSE").

[0165] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, V308P, H433R, and N434Y, and one or more amino acid substitution(s) selected from the group consisting of G237D, P238D, and E328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / V308P / H433R / N434Y ("YTEPRY") and G237D / P238D / L328F ("GDPDLF").

[0166] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252Y, S254T, T256E, V308P, H433R, and N434Y, and one or more amino acid substitution(s) selected from the group consisting of G236D, G237D, P238D, and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / V308P / H433R / N434Y ("YTEPRY") and G236D / G237D / P238D / L328F ("GDGDPDLF").

[0167] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252W, V308P, H433R, and N434Y, and one or more amino acid substitution(s) selected from the group consisting of G236D and S267E. In some embodiments, the modified Fc domain includes amino acid substitutions of M252W / V308P / H433R / N434Y ("WPRY") and G236D / S267E ("DE").

[0168] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252W, V308P, H433R, and N434Y, and one or more amino acid substitution(s) selected from the group consisting of G236D and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252W / V308P / H433R / N434Y ("WPRY") and G236D / L328F ("GDLF").

[0169] In some embodiments, the modified Fc domain includes one or more amino acid mutation(s) selected from the group consisting of M252W, V308P, H433R, and N434Y, and one or more amino acid mutation(s) selected from the group consisting of AG236 and S267E.In some embodiments, the modified Fc domain includes amino acid substitutions of M252W / V308P / H433R / N434Y ("WPRY"), an amino acid deletion of AG236, and an amino acid substitution of S267E ("AGSE").

[0170] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252W, V308P, H433R, and N434Y, and one or more amino acid substitution(s) selected from the group consisting of G237D, P238D, and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252W / V308P / H433R / N434Y ("WPRY") and G237D / P238D / L328F ("GDPDLF").

[0171] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252W, V308P, H433R, and N434Y, and one or more amino acid substitution(s) selected from the group consisting of G236D, G237D, P238D, and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252W / V308P / H433R / N434Y ("WPRY") and G236D / G237D / P238D / L328F ("GDGDPDLF").

[0172] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252W, V308P, and N434F, and one or more amino acid substitution(s) selected from the group consisting of G236D and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252W / V308P / N434F ("WPF") and G236D / L328F ("GDLF").

[0173] In some embodiments, the modified Fc domain includes one or more amino acid mutation(s) selected from the group consisting of M252W, V308P, and N434F, and one or more amino acid mutation(s) selected from the group consisting of AG236 and S267E. In some embodiments, the modified Fc domain includes amino acid substitutions of M252W / V308P / N434F ("WPF"), an amino acid deletion of AG236, and an amino acid substitution of S267E ("AGSE").

[0174] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252W, V308P, and N434F, and one or more amino acid substitution(s) selected from the group consisting of G237D, P238D, and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252W / V308P / N434F ("WPF") and G237D / P238D / L328F ("GDPDLF").

[0175] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252W, V308P, and N434F, and one or more amino acid substitution(s) selected from the group consisting of G236D, G237D, P238D, and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252W / V308P / N434F ("WPF") and G236D / G237D / P238D / L328F ("GDGDPDLF").

[0176] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252W and N434W, and one or more amino acid substitution(s) selected from the group consisting of G236D and S267E. In some embodiments, the modified Fc domain includes amino acid substitutions of M252W / N434W ("WW") and G236D / S267E ("DE").

[0177] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252W and N434W, and one or more amino acid substitution(s) selected from the group consisting of G236D and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252W / N434W ("WW") and G236D / L328F ("GDLF").

[0178] In some embodiments, the modified Fc domain includes one or more amino acid mutation(s) selected from the group consisting of M252W and N434W, and one or more amino acid mutation(s) selected from the group consisting of AG236 and S267E. In some embodiments, the modified Fc domain includes amino acid substitutions of M252W / N434W ("WW"), an amino acid deletion of AG236, and an amino acid substitution of S267E ("AGSE").

[0179] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252W and N434W, and one or more amino acid substitution(s) selected from the group consisting of G237D, P238D, and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252W / N434W ("WW") and G237D / P238D / L328F ("GDPDLF").

[0180] In some embodiments, the modified Fc domain includes one or more amino acid substitution(s) selected from the group consisting of M252W and N434W, and one or more amino acid substitution(s) selected from the group consisting of G236D, G237D, P238D, and L328F. In some embodiments, the modified Fc domain includes amino acid substitutions of M252W / N434W ("WW") and G236D / G237D / P238D / L328F ("GDGDPDLF").

[0181] In some embodiments, the modified Fc domain includes: (i) a tyrosine (Y) substitution at amino acid position 252, (ii) a threonine (T) substitution at amino acid position 254, (iii) a glutamic acid (E) substitution at amino acid position 256, (iv) a lysine (K) substitution at amino acid position 433, (v) a phenylalanine (F) substitution at amino acid position 434, (vi) a glutamic acid (E) substitution at amino acid position 267, (vii) a phenylalanine (F) substitution at amino acid position 328. In some embodiments the modified Fc domain further includes a phenylalanine (F) at position 243, a valine (V) at position 264, or both. In some embodiments, the modified Fc domain includes one or more members selected from the group consisting of a leucine (L) at amino acid position 234, a leucine (L) at amino acid position 235, and a proline (P) at amino acid position 329. In some embodiments, the modified Fc domain includes one or more members selected from one or more members selected from the group consisting of a threonine (T) at amino acid position 250, a methionine (M) at amino acid position 428, and an asparagine (N) at amino acid position 325. In some embodiments, the modified Fc domain includes at most 10 amino acid substitutions as compared to the wild-type Fc domain. In some embodiments, the modified Fc domain includes at most 9 amino acid substitutions as compared to the wild-type Fc domain. In some embodiments, the modified Fc domain includes at most 8 amino acid substitutions as compared to the wild-type Fc domain. In some embodiments, the modified Fc domain includes at most 7 amino acid substitutions as compared to the wild-type Fc domain.

[0182] In some embodiments, the modified Fc domain includes: (i) a tyrosine (Y) substitution at amino acid position 252, (ii) a threonine (T) substitution at amino acid position 254, (iii) a glutamic acid (E) substitution at amino acid position 256, (iv) a proline (P) substitution at amino acid position 308, (v) a tyrosine (Y) substitution at amino acid position 434, (vi) a glutamic acid (E) substitution at amino acid position 267, (vii) a phenylalanine (F) substitution at amino acid position 328. In some embodiments the modified Fc domain further includes a phenylalanine (F) at position 243, a valine (V) at position 264, or both. In some embodiments, the modified Fc domain includes one or more members selected from the group consisting of a leucine (L) at amino acid position 234, a leucine (L) at amino acid position 235, and a proline (P) at amino acid position 329. In some embodiments, the modified Fc domain includes one or more members selected from one or more members selected from the group consisting of a threonine (T) at amino acid position 250, a methionine (M) at amino acid position 428, and an asparagine (N) at amino acid position 325. In some embodiments, the modified Fc domainincludes at most 8 amino acid substitutions as compared to the wild-type Fc domain. In some embodiments, the modified Fc domain includes at most 7 amino acid substitutions as compared to the wild-type Fc domain.

[0183] In some embodiments, the modified Fc domain does not comprise a F243A substitution. In some embodiments, the modified Fc domain does not comprise a V264A substitution. In some embodiments, the modified Fc domain does not comprise a T250Q substitution. In some embodiments, the modified Fc domain does not comprise a M428L substitution. In some embodiments, the modified Fc domain does not comprise a N325S substitution. In some embodiments, the modified Fc domain does not comprise a L234A substitution. In some embodiments, the modified Fc domain does not comprise a L235A substitution. In some embodiments, the modified Fc domain does not comprise a P329A substitution. In some embodiments, the modified Fc domain does not comprise a P329G substitution.

[0184] In some embodiments, the modified Fc domain has or includes an amino acid sequence having at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to one selected from the group consisting of SEQ ID NOs: 2-19. In some embodiments, the modified Fc domain has or includes the amino acid sequence selected from the group consisting of SEQ ID NOs: 2-19, as shown in Table 4. In some embodiments, the modified Fc domain has or includes the amino acid sequence of SEQ ID NO: 4, as shown in Table 4. In some embodiments, the modified Fc domain has or includes the amino acid sequence of SEQ ID NO: 5, as shown in Table 4.

[0185] In some embodiments, the modified Fc domain includes amino acid substitutions of M252Y / S254T / T256E / H433K / N434F ("YTEKF") and S267E / L328F ("SELF"). When introduced as part of human IgGl, the modified Fc domain may bind FcRn in neutral pH (e.g., pH 7.4) with a KD of between about 500 picomolar (pM) to about 610 pM, between about 525 pM to about 580 pM, or about 554 pM, as ascertained by a Bio-Layer Interferometry (BLI) assay. When introduced as part of human IgGl, the modified Fc domain may bind FcRn in acidic pH (e.g., pH 6.0) with a KD of between about 255 picomolar (pM) to about 315 pM, between about 270 pM to about 300 pM, or about 285 pM, as ascertained by the BLI assay. When introduced as part of human IgGl, the modified Fc domain may bind FcyRIIB with a KD of between about 23 nanomolar (nM) to about 30 nM, between about 24 nM to about 28 nM, or about 26 nM, as ascertained by the BLI assay.

[0186] In certain embodiments, the modified Fc domains provided herein form a dimeric Fc region. In some cases, two identical Fc domains form a homodimer (e.g., to form a bivalent antibody). In some cases, two different Fc domains can form a heterodimer (e.g., to form a monovalent antibody) with mutations to the one or two individual chain via, for example, a knob-into-hole (KiH), a disulfide bond (-S-S-), or via hydrophobic interaction, electrostatic interaction, hydrophilic interaction, or increased flexibility. The Fc domain pairing can be achieved by forming a heterodimer via knob-into-hole (KIH), hydrophobic interaction, electrostatic interaction, hydrophilic interaction, or increased flexibility. For example, the KiH mutations may include T366W (knob) and T366S / L368A / Y407V(hole), S354C7T366W (knob) and Y349C / T366S / L368A / Y407V (hole), T366Y(knob) and Y407T(holc), F405A(knob) and T394W(hole), T366Y / F405A(knob) and T394W / Y407T(hole), or T366W(knob) and Y407A(hole).

[0187] In certain embodiments, the Fc region provided herein is a heterodimer including knob-into-hole (KiH) mutations in its respective chains. In certain embodiments, the first heavy chain of the Fc heterodimer includes T366W (knob), and the second heavy chain includesT366S / L368 A / Y407 V(holc) .

[0188] In certain embodiments, the modified Fc domain provided herein includes KiH mutations in its respective chains, in combination with one or more modifications that increase the binding of the Fc domains to human FcRn and / or modifications to increase binding of the Fc domains to human Fey RUB, such that the binding to both human FcRn and human FcyRIIB.

[0189] In certain embodiments, the modified Fc domain provided herein includes the sequence pair selected from the group consisting of SEQ ID NOs: 66 / 41, 67 / 43, 68 / 45, 69 / 47 and 70 / 49, as shown in Table 2. In certain embodiments, the modified Fc domain provided herein includes a sequence pair having at least 80% (e.g., at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity to the group consisting of SEQ ID NO: 68 / 45 and 70 / 49.Table 2. Sequences of modified Fc domain containing KiH and mutants increasing FcRn and / or FcyRIIB bindingSEQFc domain Amino acid sequence ID NO:DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCWVDVSHEDPE VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS HC1 NKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSD 65 hlgGl Fc IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVM (WT) HEALHNHYTQKSLSLSPGKHeavy DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCWVDVSHEDPE Chain VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS HC2 NKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSD 39 IAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVM HEALHNHYTQKSLSLSPGK DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCWVDVEHEDPE VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS HC1 NKAFPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSD 66 IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVM“SELF” HEALHNHYTQKSLSLSPGK(S267E / L DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCWVDVEHEDPE 328F) VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS HC2 NKAFPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSD 41 IAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVM HEALHNHYTQKSLSLSPGK DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVWDVSHEDPE VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTPLHQDWLNGKEYKCKVS IIC1 NKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSD 67 “YTEPY” IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVM (M252Y / S HEALHYHYTQKSLSLSPGK254T / T256E / V308P DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVWDVSHEDPE / N434Y) VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTPLHQDWLNGKEYKCKVS HC2 NKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSD 43 IAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVM HEALHYHYTQKSLSLSPGK DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVWDVEHEDPE“YTEPY- VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTPLHQDWLNGKEYKCKVS SELF” HC1 NKAFPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSD 68 (M252Y / S IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVM 254T / T25 HEALHYHYTQKSLSLSPGK6E / S267E DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVWDVEHEDPE / VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTPLHQDWLNGKEYKCKVS V3O8P / L3 HC2 NKAFPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSD 45 28F7 IAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVM N434Y) HEALHYHYTQKSLSLSPGK DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVWDVSHEDPE VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS NKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSD“YTEKF” HC1 69IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVM(M252Y / S HEALKFHYTQKSLSLSPGK254T / T256E / H433 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVWDVSHEDPE K / N434F) VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS HC2 NKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSD 47 IAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALKFHYTQKSLSLSPGKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVWDVEHEDPE “YTEKF- VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS SELF” HC1 NKAFPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSD 70 (M252Y / S IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVM 254T / T25 HEALKFHYTQKSLSLSPGK6E / H433 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVWDVEHEDPE K / N434F VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS S267E / L3 HC2 NKAFPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSD 49 28F) IAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALKFHYTQKSLSLSPGK

[0190] In certain embodiments, the modified Fc domain includes R292C and V302C substitutions that form an intradomain disulfide bond within the CH2 domain to increase physical stability (“CC mutant”). In certain embodiments, the modified Fc domain including the R292C / V302C substitutions may be combined with one or more additional Fc mutations that enhance FcRn and / or FcyRIIB binding shown above. In certain embodiments, the modified Fc domain including the R292C / V302C substitutions may be combined with one or more additional Fc mutations that enhance FcRn and / or FcyRIIB binding, and KiH mutations shown above.

[0191] In certain embodiments, the modified Fc domain provided herein includes the sequence pair selected from the group consisting of SEQ ID NOs: 71 / 54, 72 / 56, 73 / 58, 74 / 60, 75 / 62 and 76 / 64, as shown in Table 3. In certain embodiments, the modified Fc domain provided herein includes a sequence pair having at least 80% (e.g., at least 85%, at least 90%, at least 95%, at least 98%, or at least 99%) sequence identity to the group consisting of SEQ ID NO: 71 / 54, 72 / 56, 73 / 58, 74 / 60, 75 / 62 and 76 / 64.Table 3. Sequences of modified Fc domain containing KiH, CC mutant and mutants increasing FcRn and / or FcyRIIB bindingChain Amino acid sequence SEQ ID NO: DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLWISRTPEVTCW VDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTYRCVSVL TPLHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKGQPREPQVY HC1 TLPPSRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYK 71 “WPF-SELF” + TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHFH“CC mutant” YTQKSLSLSPGKM252W / S267E / R29 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLWISRTPEVTCW 2C / V302C / V308P / L VDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTYRCVSVL 328F / N434F TPLHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKGQPREPQVYHC2 TLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYK 54 TTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHFHYTQKSLSLSPGKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCW VDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTYRCVSVL TPLHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKGQPREPQVY HC1 72 ”YTEPY-SELF”+ TLPPSRDELTKNQVSLWCLVKGFYPSD IAVEWESNGQPENNYK “CC mutant” TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHYH M252Y / S254T / T25 YTQKSLSLSPGK6E / S267E / R292C / V DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCW 302C / V308P / L328F VDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTYRCVSVL / N434Y TPLHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKGQPREPQVY HC2 TLPPSRDELTKNQVSLSCAVKGFYPSD IAVEWESNGQPENNYK 56 TTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHYH YTQKSLSLSPGK DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCW VDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTYRCVSVL TVLHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKGQPREPQVY“YTEW-SELF” + HC1 TLPPSRDELTKNQVSLWCLVKGFYPSD IAVEWESNGQPENNYK 73 ”CC mutant” TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHWH M252Y / S254T / T25 YTQKSLSLSPGK6E / S267E / R292C / V DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCW 302C / L328F / N434 VDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTYRCVSVL W TVLHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKGQPREPQVY HC2 TLPPSRDELTKNQVSLSCAVKGFYPSD IAVEWESNGQPENNYK 58 TTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHWH YTQKSLSLSPGK DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYISRTPEVTCW VDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTYRCVSVL TPLHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKGQPREPQVY”YPY-SELF”+ “CC HC1 TLPPSRDELTKNQVSLWCLVKGFYPSD IAVEWESNGQPENNYK 74 mutant” TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHYH M252Y / S267E / YTQKSLSLSPGKR292C / V302C / DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYISRTPEVTCW V308P / N434Y / VDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTYRCVSVL L328F TPLHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKGQPREPQVY HC2 TLPPSRDELTKNQVSLSCAVKGFYPSD IAVEWESNGQPENNYK 60 TTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHYH YTQKSLSLSPGK DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCW VDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTYRCVSVL“YTEPRY- TPLHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKGQPREPQVY HC1 TLPPSRDELTKNQVSLWCLVKGFYPSD IAVEWESNGQPENNYK 75 SELF”+ “CCmutant” TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALRYH M252Y / S254I7T25 YTQKSLSLSPGK6E / S267E / DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCW R292C / V302C / V30 VDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTYRCVSVL 8P / L328F / TPLHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKGQPREPQVY HC2 TLPPSRDELTKNQVSLSCAVKGFYPSD IAVEWESNGQPENNYK 62 H433R / N434YTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALRYH YTQKSLSLSPGK DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLWISRTPEVTCW“WPRY-SELF” VDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTYRCVSVL +“CC mutant” TPLHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKGQPREPQVY HC1 TLPPSRDELTKNQVSLWCLVKGFYPSD IAVEWESNGQPENNYK 76 M252W / S267E / R292C / V302C / TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALRYHYTQKSLSLSPGKV308P / L328F / DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLWISRTPEVTCW H433R / N434Y VDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTYRCVSVL TPLHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKGQPREPQVY HC2 TLPPSRDELTKNQVSLSCAVKGFYPSD IAVEWESNGQPENNYK 64TTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALRYHYTQKSLSLSPGKFusion Proteins including modified Fc domains

[0192] Also provided herein is a fusion protein including the modified Fc domain described herein and one or more polypeptides operably fused to the modified Fc domain. In some embodiments, the polypeptide may be fused to the modified Fc domain via linker. In some embodiments, the fusion protein includes one polypeptide operably fused to the modified Fc domain (“monovalent’’). In some embodiments, the fusion protein includes two polypeptides each operably fused to the modified Fc domain (“bivalent”). In certain embodiments, the polypeptide is fused to the N-terminus of the modified Fc domain. In certain embodiments, the polypeptide is fused to the C-terminus of the modified Fc domain.

[0193] As described herein, the polypeptide (e.g., an antigen-binding domain) may be linked to the N-terminus or the C-terminus of the modified Fc domain. Alternatively, the polypeptide may to linked at a position other than the N-terminus or the C-terminus of the modified Fc domain.

[0194] In some embodiments, the polypeptide may be non-covalcntly linked to the modified Fc domain. In some embodiments, the polypeptide may be covalently linked to the modified Fc domain.

[0195] In some embodiments, the polypeptide may be linked (e.g., fused) directly to the N-terminus or the C-terminus of a modified Fc domain. In some embodiments, the polypeptide is linked to the N-terminus or the C-terminus of an modified Fc domain via a linker. In some embodiments, the linker is a non-clcavablc linker.

[0196] In some embodiments, the polypeptide may be linked (e.g., fused) directly to the N-terminus or the C-terminus of an Fc domain. In some embodiments, the polypeptide is linked to the N-terminus or the C-terminus of an Fc domain via a linker. In some embodiments, the linker is a non-cleavable linker. As used herein, the term “non-cleavable linker” refers to a linker that is not readily cleaved by one or more of a given enzyme, chemical agent, or photo-irradiation. In some embodiments, the enzyme is a protease.

[0197] In some embodiments, the linker is a synthetic compound linker such as, for example, a chemical cross-linking agent. Non-limiting examples of suitable cross-linking agents that are available on the market include N-hydroxysuccinimide (NHS), disuccinimidylsuberate (DSS), bis(sulfosuccinimidyl)suberate (BS3), dithiobis(succinimidylpropionate) (DSP), dithiobis(sulfosuccinimidylpropionate) (DTSSP), ethyleneglycol bis(succinimidylsuccinate) (EGS), ethyleneglycol bis(sulfosuccinimidylsuccinate) (sulfo-EGS), disuccinimidyl tartrate (DST), disulfosuccinimidyl tartrate (sulfo-DST), bis[2-(succinimidooxycarbonyloxy)ethyl]sulfone (BSOCOES), and bis[2-(sulfosuccinimidooxycarbonyloxy)ethyl]sulfone (sulfo-BSOCOES).

[0198] As described above, Fc domains disclosed herein may comprise a portion of a hinge region. As such, the polypeptide may be linked to the N-terminus of an Fc domain via this hinge region. In some embodiments, one or more amino acids are included between the C-terminus of the polypeptide and the N-terminus of the Fc domain. In some embodiments, the one or more amino acids included between the C-terminus of the polypeptide and the N-terminus of the Fc domain are amino acids of a natural hinge region. In some embodiments, the C-tcrminus of the polypeptide is fused to the N-terminus of the Fc domain via a hinge region or a portion thereof. In some embodiments, the hinge region is and IgG hinge region, such as a human IgG hinge region.

[0199] In some embodiments, the linker is a peptide linker. Examples of peptide linkers are well known and those of skill in the art could select a suitable peptide linker for use in linking an polypeptide to an modified Fc domain, e.g., an Fc domain.

[0200] Peptide linkers may be of any length. In some embodiments, the length and amino acid composition of the linker peptide sequence can be optimized to vary the orientation and / or proximity of the polypeptide domains to one another to achieve a desired activity of the FcRn / antigen-binding molecule. In some embodiments, the peptide linker is between about 1 and about 100 amino acids in length, between about 8 and about 40 amino acids in length, or between about 15 amino acids and about 25 amino acids in length. In some embodiments, the peptide linker is between 1 and 100 amino acids in length, between 8 and 40 amino acids in length, or between 15 and 25 amino acids in length. In some embodiments, the peptide linker is about 8 amino acid in length, about 9 amino acids in length, about 10 amino acids in length, about 11 amino acids in length, about 12 amino acids in length, about 13 amino acids in length, about 14 amino acids in length, about 15 amino acids in length, about 16 amino acids in length,about 17 amino acids in length, about 18 amino acids in length, about 19 amino acids in length, about 20 amino acids in length, about 21 amino acids in length, about 22 amino acids in length, about 23 amino acids in length, about 24 amino acids in length, about 25 amino acids in length, about 26 amino acids in length, about 27 amino acids in length, about 28 amino acids in length, about 29 amino acids in length, about 30 amino acids in length, about 31 amino acids in length, about 32 amino acids in length, about 33 amino acids in length, about 34 amino acids in length, about 35 amino acids in length, about 36 amino acids in length, about 37 amino acids in length, about 38 amino acids in length, about 39 amino acids in length, or about 40 amino acids in length. In some embodiments, the peptide linker is 8 amino acids in length, 9 amino acids in length, 10 amino acids in length, 11 amino acids in length, 12 amino acids in length, 13 amino acids in length, 14 amino acids in length, 15 amino acids in length, 16 amino acids in length, 17 amino acids in length, 18 amino acids in length, 1 amino acids in length, 20 amino acids in length, 21 amino acids in length, 22 amino acids in length, 23 amino acids in length, 24 amino acids in length, 25 amino acids in length, 26 amino acids in length, 27 amino acids in length, 28 amino acids in length, 29 amino acids in length, 30 amino acids in length, 31 amino acids in length, 32 amino acids in length, 33 amino acids in length, 34 amino acids in length, 35 amino acids in length, 36 amino acids in length, 37 amino acids in length, 38 amino acids in length, 39 amino acids in length, or 40 amino acids in length.

[0201] In some embodiments, the peptide linker contains only glycine and / or serine residues (e.g., glycine-serine linker or GS linker). Examples of such peptide linkers include: Gly(x) Ser, where x is 0 to 6; or Ser Gly(x), where x is 0 to 6; (Gly Gly Gly Gly Ser)n(SEQ ID NO: 20), wherein n is an integer of one or more; and (Ser Gly Gly Gly Gly)n(SEQ ID NO: 21), wherein n is an integer of one or more. In some embodiments, the peptide linker includes an amino acid sequence selected from the group consisting of: (GGGGS)n(SEQ ID NO: 22) and (SGGGG)n(SEQ ID NO: 23), where n is 1 to 8. In some embodiments, the linker peptides are modified such that the amino acid sequence GSG (that occurs at the junction of traditional Gly / Ser linker peptide repeats) is not present. For example, in some embodiments, the peptide linker includes an amino acid sequence selected from the group consisting of: (GGGXX)nGGGGS (SEQ ID NO: 24) and GGGGS(XGGGS)n(SEQ ID NO: 25), where X is any amino acid that can be inserted into the sequence and not result in a polypeptide including the sequence GSG, and n is 0 to 4. In some embodiments, the sequence of a linker peptide is (GGGX1X2)nGGGGS (SEQ ID NO: 26) and X1is P and X2is S and n is 0 to 4. In some other embodiments, the sequence of alinker peptide is (GGGX1X2)nGGGGS (SEQ ID NO: 27) and X1is G and X2is Q and n is 0 to 4. In some other embodiments, the sequence of a linker peptide is (GGGX1X2)nGGGGS (SEQ ID NO: 28) and X1is G and X2is A and n is 0 to 4. In yet other embodiments, the sequence of a linker peptide is GGGGS(XGGGS)n(SEQ ID NO: 29), and X is P and n is 0 to 4. In some embodiments, a linker peptide of the disclosure comprises or consists of the amino acid sequence (GGGGA^GGGGS (SEQ ID NO: 30). In some embodiments, a linker peptide comprises or consists of the amino acid sequence (GGGGQ GGGGS (SEQ ID NO: 31). In another embodiment, a linker peptide comprises or consists of the amino acid sequence (GGGPS)2GGGGS (SEQ ID NO: 32). In another embodiment, a linker peptide comprises or consists of the amino acid sequence GGGGS(PGGGS)2 (SEQ ID NO: 33). In yet a further embodiment, a linker peptide comprises or consists of the amino acid sequence GSGGS (SEQ ID NO: 34) or SGGSGS (SEQ ID NO: 35).

[0202] In some embodiments at least 50% of the amino acids comprised by the linker sequence are glycine or serine residues, e.g. at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or more are glycine or serine residues. In some embodiments, the linker sequence consists of glycine and serine residues.

[0203] In some embodiments, the linker is (GS)n, (GGGS)n (SEQ ID NO: 78), (GGGGS)n (SEQ ID NO: 79), or (GSGGS)n (SEQ ID NO: 36), wherein the n is any integer between 1-5. In some embodiments, the peptide linker includes an amino acid sequence of GGGGSGGGGSGGGGS (SEQ ID NO: 77), or GGGGSGGGGS (SEQ ID NO: 80).

[0204] In certain embodiments, the fusion protein includes an antigen-binding fragment fused to the modified Fc domain. The antigen-binding fragment may have any suitable format, such as Fab, Fab’, F(ab’)2, scFv, or VHH. In some embodiments, the fusion protein includes two or more different antigen-binding fragments, such that the fusion protein is bispecific or multi specific.

[0205] In certain embodiments, the antigen-binding fragment is fused to the N-temrinus of the modified Fc domain. In certain embodiments, the antigen-binding fragment is fused to the C-terminus of the modified Fc domain.

[0206] In certain embodiments, the target antigen of the antigen-binding fragment can be an autoantibody (e.g., human IgG), and the antigen-binding fragment may comprise an autoantibody -binding domain. In certain embodiments, the fusion protein includes anautoantibody-binding domain fused to the modified Fc domain. In some embodiments, the autoantibody-binding domains have binding specificity to human autoantibodies. In certain embodiments, the target antigen of the antigen-binding fragment as provided herein can be an autoantigen, and the antigen-binding fragment may comprise an autoantigen-binding domain. In some embodiments, the autoantibody- or autoantigen-binding domains have binding specificity to IgA, IgG, or Ig li. In some embodiments, the autoantibody- or autoantigen-binding domains have any suitable format, such as Fab, Fab’, F(ab’)2, scFv, or VHH.

[0207] In some embodiments, the autoantibody-binding domains includes or mimics the target molecule of the autoantibodies. For example, the autoantibody-binding domain includes a fragment and / or variant of the target molecule of the autoantibodies.

[0208] In certain embodiments, depletion of autoantibodies or autoantigens is achieved by promoting cellular uptake of immune complexes comprising the autoantibodies or autoantigens and delivery of such immune complexes to lysosomes for degradation.

[0209] In certain embodiments, the fusion protein comprising the antigen-binding domain and the modified Fc domain has a structure represented in one of Formats 1-4 as illustrated in FIG.5. In some cases, the fusion protein can be a bivalent antibody having the structure of Format 3 (e.g., the antigen-binding domain is coupled to or fused to the N-terminus of the modified Fc domain) or Format 4 (e.g., the antigen-binding domain is coupled to or fused to the C-terminus of the modified Fc domain). In some cases, the fusion protein can be a monovalent antibody having the structure of Format 1 (e.g., the antigen-binding domain is coupled to or fused to the N-terminus of the modified Fc domain) or Format 2 (e.g., the antigen-binding domain is coupled to or fused to the C-terminus of the modified Fc domain).

[0210] In certain embodiments, the autoantibody-binding domain has the binding specificity to human IgAl (hlgAl) and mediates the internalization of the hlgAl, thereby facilitates the clearance of the serum hlgAl.

[0211] In certain embodiments, the autoantibody-binding domain includes the heavy chain variable region and the light chain variable region of HISA43, an anti-human IgAl mouse antibody that specifically recognizes and binds to an epitope located within the Fc region of human IgAl (hlgAl).

[0212] In certain embodiments, the variable region of HIS A43 includes a heavy chain variable region having the sequence of SEQ ID NO: 81 and a light chain variable region having the sequence of SEQ ID NO: 82.

[0213] In certain embodiments, the variable region of HIS A43 is fused to the N-terminus of the modified Fc domain provided herein. In certain embodiments, the variable region of HIS A43 is fused to one chain of the heterodimeric modified Fc domain provided herein.

[0214] In certain embodiments, the fusion protein including the HISA43 antibody variable region and the modified Fc domain entails a light chain / heavy chain 1 / heavy chain 2 combination selected from the group consisting of SEQ ID NOs: 37 / 38 / 39, 37 / 40 / 41, 37 / 42 / 43, 37 / 44 / 45, 37 / 46 / 47, and 37 / 48 / 49, as shown in Table 6.

[0215] In certain embodiments, the autoantibody-binding domain of the fusion protein provided herein entails a binding domain having the binding specificity to autoantibodies against NC16A region of human BP180 (COL17A1).

[0216] In certain embodiments, the anti-NC16A autoantibody binding domain disclosed herein bind to multiple paratopes of the autoantibodies in the human body, thereby accelerates clearance of circulating anti-NC16A autoantibodies. In certain embodiments, the anti-NC16A autoantibody binding domain disclosed herein bind to N-terminus and / or C-terminus of the NC16A domain.

[0217] In certain embodiments, the autoantibody -binding domain of the fusion protein provided herein includes truncated NC16A fragment (including amino acids 514-566) of human BP180 / COL17A1 protein or human NC16A (aa 490-566 of human BP180).

[0218] In certain embodiments, the truncated NC16A fragment includes the amino acid sequence of SEQ ID NO: 50, as shown in Table 7. In certain embodiments, the human includes the amino acid sequence of SEQ ID NO: 83.

[0219] NC16A In certain embodiments, the truncated NC16A fragment is fused to the C-terminus of the modified Fc domain provided herein.

[0220] In certain embodiments, the truncated NC16A fragment is fused to modified Fc domain provided herein via a peptide linker.

[0221] In certain embodiments, the truncated NC16A fragment is fused to one chain of the heterodimeric modified Fc domain provided herein.

[0222] In certain embodiments, the fusion protein entailing the truncated NC16A fragment and the modified Fc domain includes a heavy chain 1 / heavy chain 2 combination selected from the group consisting of SEQ ID NOs: 53 / 54, 55 / 56, 57 / 58, 59 / 60, 61 / 62, 63 / 64, 84 / 85, 86 / 87, 88 / 89, 90 / 91, 92 / 93, 94 / 95, and 96 / 97, as shown in Table 7.

[0223] In certain embodiments, the modified Fc domain or the fusion protein described herein lacks an asialoglycoprotein receptor (ASGPR)-binding moiety.

[0224] As used herein, an “asialoglycoprotein receptor (ASGPR)-binding moiety” refers to any chemical group, ligand, peptide, carbohydrate, small molecule, oligonucleotide, polymer, or other molecular entity that is comprised within, associated with, fused to, or conjugated (directly or indirectly) to a modified Fc domain or a fusion protein described herein and that specifically binds to ASGPR (e.g., ASGPR1 and / or ASGPR2), thereby conferring ASGPR-mediated targeting and / or disposition of the modified Fc domain or fusion protein (e.g., hepatocyte targeting, cell surface association, receptor-mediated internalization, cndosomal uptake, tissue distribution, and / or clearance). In some embodiments, the ASGPR-binding moiety comprises a carbohydrate-containing ligand that presents terminal galactose and / or N-acetylgalactosamine (GalNAc) residues and may be mono-, bi-, or multivalent; however, the term is not limited to any particular chemical class, valency, or ligand architecture, provided that the moiety binds ASGPR.Methods of Treatments

[0225] In one aspect, the present disclosure provides methods of treating a subject (e.g., a human patient) in need thereof comprising administering a therapeutically effective amount of the modified Fc domain, the fusion protein or the composition disclosed herein. In certain embodiments, the present disclosure provides articles of manufacture (e.g., kits) for use in such treatment methods.

[0226] The patient has an IgG-mediated disease or disorder and will benefit from faster clearance of serum IgG by being treated with the modified Fc domain or the fusion protein described herein of the present disclosure. As used herein, the terms “antibody-related,” “antibody-mediated,” and “antibody-responsive” disorder, condition, or disease refer to a disorder, condition, or disease that may be ameliorated by removal undcsircd antibody (e.g., certain autoreactive IgG, or exogenously provided therapeutic or diagnostic IgG that is no longer needed or beneficial to the patient).

[0227] One embodiment provides a method of suppressing an IgG-mediated disease or disorder in a patient in need thereof. The method entails administering to the patient modified Fc domain, the fusion protein or the composition of the present disclosure. In some embodiments, the patient is a tissue or organ transplant recipient.

[0228] In certain embodiments, the IgG-mediated disorder may be, an autoimmune disease.

[0229] In certain embodiments, the patient has an IgA-mediated disease or disorder, which is an autoimmune disease.

[0230] In certain embodiments, the patient has an autoimmune blistering disease and will benefit from faster clearance of anti-NC16A autoantibody by being treated with the recombinant fusion protein described herein of the present disclosure.

[0231] One embodiment provides a method of suppressing an anti-NC16A autoantibody-mediated disease or disorder in a patient in need thereof. The method entails administering to the patient the fusion protein including the anti-NC16A autoantibody binding domain or the composition of the present disclosure.

[0232] In certain embodiments, the anti-NC16A autoantibody-mediated disorder may be, an autoimmune disease.

[0233] In certain embodiments, the recombinant fusion protein disclosed herein can be used to selectively targets and depletes pathogenic autoantibodies (i.e., anti-NC16Al antibodies) to treat multiple autoimmune diseases.

[0234] An “autoimmune disease” herein is a disease or disorder arising from and directed against an individual's own (self) tissues and / or antigen or a co-segregate or manifestation thereof or resulting condition therefrom. Examples of autoimmune diseases or disorders include, but are not limited to arthritis (rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis, and ankylosing spondylitis), psoriasis, dermatitis including atopic dermatitis; chronic idiopathic urticaria, including chronic autoimmune urticaria, polymyositis / dermatomyositis, toxic epidermal necrolysis, systemic scleroderma and sclerosis, responses associated with inflammatory bowel disease (IBD) (Crohn's disease, ulcerative colitis), and IBD with co-segregate of pyoderma gangrenosum, erythema nodosum, primary sclerosing cholangitis, and / or episcleritis), respiratory distress syndrome, including adult respiratory distress syndrome (ARDS), meningitis, IgE-mediated diseases such as anaphylaxis and allergic rhinitis, encephalitis such as Rasmussen's encephalitis, uveitis, colitis such asmicroscopic colitis and collagenous colitis, glomerulonephritis (GN) such as membranous GN, idiopathic membranous GN, membranous proliferative GN (MPGN), including Type I and Type II, and rapidly progressive GN, allergic conditions, eczema, asthma, conditions involving infiltration of T cells and chronic inflammatory responses, atherosclerosis, autoimmune myocarditis, leukocyte adhesion deficiency, systemic lupus erythematosus (SLE) such as cutaneous SLE, lupus (including nephritis, cerebritis, pediatric, non-renal, discoid, alopecia), juvenile onset diabetes, multiple sclerosis (MS) such as spino-optical MS, allergic encephalomyelitis, immune responses associated with acute and delayed hypersensitivity mediated by cytokines and T-lymphocytes, tuberculosis, sarcoidosis, granulomatosis including Wegener's granulomatosis, agranulocytosis, vasculitis (including Large Vessel vasculitis (including Polymyalgia Rheumatica and Giant Cell (Takayasu’s) Arteritis), Medium Vessel vasculitis (including Kawasaki's Disease and Polyarteritis Nodosa), CNS vasculitis, and ANCA-associated vasculitis, such as Churg-Strauss vasculitis or syndrome (CSS), aplastic anemia, Coombs positive anemia, Diamond Blackfan anemia, immune hemolytic anemia including autoimmune hemolytic anemia (AIHA), pernicious anemia, pure red cell aplasia (PRCA), Factor VIII deficiency, hemophilia A, autoimmune neutropenia, pancytopenia, leukopenia, diseases involving leukocyte diapedesis, CNS inflammatory disorders, multiple organ injury syndrome, myasthenia gravis, antigen-antibody complex mediated diseases, anti-glomerular basement membrane disease, anti-phospholipid antibody syndrome, allergic neuritis, Bechet disease, Castleman's syndrome, Goodpasture's Syndrome, Lambert-Eaton Myasthenic Syndrome, Reynaud's syndrome, Sjorgen's syndrome, Stevens-Iohnson syndrome, solid organ transplant rejection (including pretreatment for high panel reactive antibody titers, IgA deposit in tissues, and rejection arising from renal transplantation, liver transplantation, intestinal transplantation, cardiac transplantation, etc.), graft versus host disease (GVHD), pemphigoid bullous, pemphigus (including vulgaris, foliaceus, and pemphigus mucus-membrane pemphigoid), autoimmune polyendocrinopathies, Reiter's disease, stiff-man syndrome, immune complex nephritis, IgM polyneuropathies or IgM mediated neuropathy, idiopathic thrombocytopenic purpura (ITP), thrombotic throbocytopenic purpura (TTP), thrombocytopenia (as developed by myocardial infarction patients, for example), including autoimmune thrombocytopenia, autoimmune disease of the testis and ovary including autoimmune orchitis and oophoritis, primary hypothyroidism; autoimmune endocrine diseases including autoimmune thyroiditis, chronic thyroiditis (Hashimoto's Thyroiditis), subacute thyroiditis, idiopathic hypothyroidism, Addison's disease, Grave's disease, autoimmune polyglandularsyndromes (or polyglandular endocrinopathy syndromes), Type I diabetes also referred to as insulin-dependent diabetes mellitus (IDDM), including pediatric IDDM, and Sheehan’s syndrome; autoimmune hepatitis, Lymphoid interstitial pneumonitis (HIV), bronchiolitis obliterans (non-transplant) vs NSIP, Guillain-Barre Syndrome, Berger's Disease (IgA nephropathy), primary biliary cirrhosis, celiac sprue (gluten enteropathy), refractory sprue with co-segregate dermatitis herpetiformis, cryoglobulinemia, amylotrophic lateral sclerosis (ALS; Lou Gehrig's disease), coronary artery disease, autoimmune inner ear disease (AIED), autoimmune hearing loss, opsoclonus myoclonus syndrome (OMS), polychondritis such as refractory polychondritis, pulmonary alveolar proteinosis, amyloidosis, giant cell hepatitis, sclcritis, monoclonal gammopathy of unccrtain / unknown significance (MGUS), peripheral neuropathy, paraneoplastic syndrome, channelopathies such as epilepsy, migraine, arrhythmia, muscular disorders, deafness, blindness, periodic paralysis, and channelopathies of the CNS; autism, inflammatory myopathy, and focal segmental glomerulosclerosis (FSGS).

[0235] In certain embodiments, the autoimmune disease includes, but are not limited to Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), Myelin oligodendrocyte glycoprotein (MOG) antibody disease, Ncuromyclitis optica (NMO), Myasthenia gravis (MG), Idiopathic inflammatory myopathy (IIM), Pemphigus vulgaris (PV), Pemphigus foliaceus (PF), Bullous pemphigoid (BP), Autoimmune thyroiditis, Graves' Ophthalmopathy (GO), Antibody mediated rejection (AMR), graft versus host disease (GVHD), Hemolytic disease of the fetus and newborn (HDFN), rheumatoid arthritis (RA), systemic sclerosis (SSc) / scleroderma, Systemic lupus erythematosus (SLE), multiple sclerosis, psoriasis / psoriatic arthritis, osteoarthritis, Lupus nephritis (LN), inflammatory bowel disease, Addison’s disease, Graves' disease, Hashimoto's thyroiditis, Primary Sjogren's syndrome (pSS), autoimmune hepatitis, type 1 diabetes, pemphigus, atopic dermatitis, bullous pemphigoid, idiopathic thrombocytopenic purpura, Warm Autoimmune Hemolytic Anemia (wAIHA), vasculitis, pernicious anemia, celiac disease, Crohn's disease, ulcerative colitis, primary sclerosing cholangitis, Autoimmune encephalitis (AE), autoimmune dermatitis, autoimmune nephritis, autoimmune myocarditis, asthma, allergy, idiopathic pulmonary fibrosis (IPF), Immune thrombocytopenic purpura (ITP), or hidradenitis suppurativa.

[0236] In certain embodiments, the autoimmune disease is the IgA-mediated disease or disorder which includes, IgA nephropathy (IgAN), IgA vasculitis (Henoch-Schonlein purpura), linearIgA bullous dermatosis, dermatitis herpetiformis, IgA pemphigus, IgA autoimmune hemolytic anemia..

[0237] In certain embodiments, the disease is the IgG-mediated disease or disorder which includes, Anti-glomerular basement membrane disease (Goodpasture's syndrome), antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, antiphospholipid syndrome, autoimmune encephalitis, autoimmune hemolytic anemia, bullous pemphigoid, chronic inflammatory demyelinating polyneuropathy (CIDP), dermatomyositis, epidermolysis bullosa acquisita, fetal and neonatal alloimmune thrombocytopenia (FNAIT), Graves' disease, Guillain-Barre syndrome, hemolytic disease of the fetus and newborn (HDFN), IgG4-related disease, immune thrombocytopenia (ITP), lupus nephritis, membranous nephropathy, mucous membrane pemphigoid, myasthenia gravis, myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), neuromyelitis optica spectrum disorder (NMOSD), pemphigus foliaceus, pemphigus vulgaris, polymyositis, rheumatoid arthritis, Sjogren's syndrome, stiffperson syndrome, systemic lupus erythematosus (SLE), thyroid eye disease (Graves' ophthalmopathy), warm autoimmune hemolytic anemia (wAIHA).

[0238] In certain embodiments, the disease is the IgE-mediated disease or disorder which includes, Systemic lupus erythematosus (SLE), bullous pemphigoid, chronic spontaneous urticaria (CSU), Hashimoto’s thyroiditis, Graves' disease, rheumatoid arthritis, multiple sclerosis, autoimmune uveitis, pemphigus vulgaris, pemphigus foliaceus, mixed connective tissue disease, atopic dermatitis.

[0239] In certain embodiments, the fusion protein disclosed herein target anti-NC16A autoantibodies to make immune complexes, which are internalized via FcRn and / or FcyRIIB and trafficked to degradative pathways, resulting in enhanced lysosomal degradation and clearance of the immune complexes.

[0240] In certain embodiments, the immune complexes so formed have enhanced binding kinetics with FcRn and / or FcyRIIB relative to an immune complex that includes the anti-NC16A autoantibodies bound to a corresponding molecule with wild-type Fc domains. Such enhanced binding kinetics increase clearance of the immune complex.

[0241] In certain embodiments, the patient has an autoimmune blistering disease. In certain embodiments, the autoimmune blistering disease includes bullous pemphigoid, pemphigoidgestations, mucous membrane pemphigoid, and drug induced bullous pemphigoid disease or disorder.

[0242] A specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including a quadruple variant with enhanced FcRn binding at pH 6.0 and pH 7.4, and / or FcyRIIB binding, the patient’s age, body weight, general health, sex, and diet, and the time of administration, rate of excretion, drag combination, and the severity of the particular disease being treated. Judgment of such factors by medical caregivers is within the ordinary skill in the art. The amount will also depend on the individual patient to be treated, the route of administration, the type of formulation, the characteristics of the compound used, the severity of the disease, and the desired effect. The amount used can be determined by pharmacological and pharmacokinetic principles well known in the art. A suitable dosage regimen may be determined in order to provide an effective therapeutic response in a subject. Dosages may be divided and administered over a certain period of time, e.g., administered daily for one week.

[0243] In certain embodiments, the modified Fc domain or the fusion protein described herein can be used to reduce serum levels of an Fc-containing agent (e.g., a therapeutic or diagnostic agent) in a subject. Clearance of an Fc-containing agent may be desired in cases where the Fc-containing agent is detrimental (e.g., toxic) to a subject, or wherein the Fc-containing reagent is only desired to be present in a subject for a certain period of time, for example, when the Fc-containing agent is immunogenic or when the Fc-containing agent is an antibody-drug conjugate, respectively. In certain embodiments, clearance of an Fc-containing agent reduces the amount of exposure of the subject to the Fc-containing agent. The level of any Fc-containing agent in the serum may be reduced by employing the modified Fc domain described herein. Accordingly, in certain embodiments, the modified Fc domain disclosed herein is used to reduce the serum levels of an Fc-containing agent in a subject that has been administered the Fc-containing agent.

[0244] In another aspect, a method of enhancing diagnostic imaging is provided comprising administering to a subject a therapeutically effective amount of the modified Fc domain disclosed herein. Modified Fc domains disclosed herein may be used to reduce both background levels and systemic exposure to radiolabeled antibody during diagnostic imaging. In certain embodiments, diagnostic imaging includes, without limitation, positron emission tomography (PET), single photon emission computed tomography (SPECT), a combination of PET and computerized tomography (CT), and the like.

[0245] In certain embodiments, a subject is administered an effective amount of a radiolabeled antibody, and optionally, the modified Fc domain is administered after administration of the radiolabeled antibody. In certain embodiments, contrast of the radiolabeled antibody is enhanced in a subject using the modified Fc domain or the fusion protein described herein e.g., by clearing unbound radiolabeled antibodies from the circulation, allowing for increased contrast (e.g., reduced background signals) and reduction in the harmful effects of exposure to radiolabeled antibodies. Accordingly, in certain embodiments, a method of reducing exposure of normal tissue to a radiolabeled antibody during diagnostic imaging comprising administering to a subject a therapeutically effective amount of the modified Fc domain or the fusion protein disclosed herein is provided.

[0246] In certain embodiments, the modified Fc domain or the fusion protein disclosed herein can be used to clear a therapeutic agent from a subject. For example, a subject administered a therapeutic agent may develop antibodies, e.g., anti-drug antibodies, that reduce the availability and / or efficacy of the administered therapeutic agent. The presence of anti-drug antibodies in a subject may result in unwanted side effects. Accordingly, the modified Fc domain or the fusion protein described herein disclosed herein remove the anti-drug antibodies that develop in a subject.

[0247] In certain embodiments, the present disclosure provides kits and methods for the diagnosis and / or treatment of disorders, e.g., an IgG-mediated disorder or IgA-mediated disorder in a mammalian subject in need of such treatment. In exemplary embodiments, the subject is a human.

[0248] Methods of administration of the modified Fc domain or the fusion protein described herein include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The antigen-binding polypeptides or compositions may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Thus, pharmaceutical compositions containing the antigen-binding polypeptides of the disclosure may be administered orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments, drops or transdermal patch), bucally, or as an oral or nasal spray.

[0249] The term “parenteral” as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intra-articular injection and infusion.

[0250] Administration can be systemic or local. In addition, it may be desirable to introduce the modified Fc domain or the fusion protein of the disclosure into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

[0251] It may be desirable to administer the modified Fc domain or the fusion protein described herein, or compositions of the disclosure locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction, with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. Preferably, when administering a protein, including an antibody, of the disclosure, care must be taken to use materials to which the protein does not absorb.

[0252] In certain embodiments, the modified Fc domain or the fusion protein described herein can be used in combination with one or more additional therapeutic agents. In certain embodiments, a combination therapy comprising the modified Fc domain or the fusion protein disclosed herein can target the innate immune system and / or the adaptive immune system, for example, by binding to and removing from circulation pro-inflammatory cytokines. In some embodiments, the modified Fc domain or the fusion protein described herein themselves can bind to and remove pro-inflammatory cytokines, achieving the combined effects of removing autoreactive serum IgG as well as pro-inflammatory cytokines. In certain embodiments, a combination therapy comprising the modified Fc domain disclosed herein can include a TLR-inhibitor, e.g., an IRAK-4 inhibitor.

[0253] The second therapeutic agent as set forth herein are generally used in the same dosages and with administration routes as used hereinbefore or about from 1 to 99% of the heretofore-employed dosages. If such additional drugs are used at all, preferably, they are used in lower amounts than if the modified Fc domain or the fusion protein described herein are not present,especially in subsequent dosing beyond the initial dosing with the modified Fc domain or the fusion protein described herein, so as to eliminate or reduce side effects caused thereby.

[0254] The combined administration of a second therapeutic agent includes co-administration (concurrent administration), using separate formulations or a single pharmaceutical formulation, and consecutive administration in either order, wherein preferably there is a time period while both (or all) therapeutic agents (medicaments) simultaneously exert their biological activities.Compositions

[0255] The present disclosure also provides pharmaceutical compositions. Such compositions comprise an effective amount of the modified Fc domains, and an acceptable carrier. In some embodiments, the composition further includes a second therapeutic agent.

[0256] In a specific embodiment, the term “pharmaceutically acceptable” means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. Further, a “pharmaceutically acceptable carrier” will generally be a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.

[0257] “Effective amount” means the amount of active pharmaceutical agent (c.g., a modified Fc domain of the present disclosure) sufficient to effectuate a desired physiological outcome in an individual in need of the agent. The effective amount may vary among individuals depending on the health and physical condition of the individual to be treated, the formulation of the composition, assessment of the individual's medical condition, and other relevant factors.

[0258] The term “carrier” refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred earner when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or Ph buffering agents such as acetates, citrates or phosphates. Antibacterial agents such as benzylalcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenedi aminetetraacetic acid; and agents for the adjustment of tonicity such as sodium chloride or dextrose are also envisioned. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and earners such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in Remington’s Pharmaceutical Sciences by E. W. Martin, incorporated herein by reference. Such compositions will contain a therapeutically effective amount of the antigenbinding polypeptide, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration. The parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

[0259] In an embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachet indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

[0260] The compounds of the disclosure can be formulated as neutral or salt forms.Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, feme hydroxides, isopropylamine, triethylamine. 2-ethylamino ethanol, histidine, procaine, etc.EXAMPLESExample 1. Modified Fc fragments

[0261] Modifications were introduced to human IgGl (hlgGl) Fc fragment, and binding affinities of hlgGl Fc and its variants to human FcRn (hFcRn) and human FcyRIIb (hFcyRIIb) were evaluated. Sequences of hlgGl Fc and its variants are shown in Table 4.Table 4. Sequences of the modified Fc fragmentsSEQFc fragment Amino acid sequence ID NO:DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCWV DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPhlgGl Fc PSRDELTKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKTTPP 1 VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCWV DVEHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTV SELF LHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKGQPREPQVYTLP PSRDELTKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKTTPP 2 (S267E / L328F)VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVV DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTP YTEPY LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP(M252Y / S254T / T256E / V308P / PSRDELTKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKTTPP 3 N434Y) VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHYHYTQKS LSLSPGK DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVV DVEHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTP YTEPY-SELF LHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKGQPREPQVYTLP (M252Y / S254T / T256E / S267E / PSRDELTKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKTTPP 4 V308P / L328F / N434Y) VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHYHYTQKS LSLSPGK DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVV DVEHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTV YTEKF-SELF LHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKGQPREPQVYTLP (M252Y / S254T / T256E / H433K PSRDELTKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKTTPP 5 / N434F, S267E / L328F) VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALKFHYTQKS LSLSPGK DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVW DVEHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTV YTE-SELF LHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKGQPREPQVYTLP (M252Y / S254T / T256E, PSRDELTKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKTTPP 6 S267E / L328F) VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVW DVEHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTV YTEW-SELF LHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKGQPREPQVYTLP (M252Y / S254T / T256EZN434W PSRDELTKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKTTPP 7 , S267E / L328F) VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHWHYTQKSLSLSPGKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYISRTPEVTCWV DVEHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTP YPY-SELF LHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKGQPREPQVYTLP (M252Y / V308P / N434Y, PSRDELTKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKTTPP 8 S267E / L328F) VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHYHYTQKS LSLSPGK DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVW DVEHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTP YTEPF-SELF LHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKGQPREPQVYTLP (M252Y / S254T / T256E / V308P / PSRDELTKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKTTPP 9 N434F, S267E / L328F) VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHFHYTQKS LSLSPGK DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVW DVEHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTP YTEPRY-SELF LHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKGQPREPQVYTLP (M252Y / S254T / T256E / V308P / PSRDELTKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKTTPP 10 H433R / N434Y, S267E / L328F) VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALRYHYTQKS LSLSPGK DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLWISRTPEVTCWV DVEHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTP WPRY-SELF LHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKGQPREPQVYTLP (M252W / V308P / H433R / N434 PSRDELTKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKTTPP 11 Y, S267E / L328F) VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALRYHYTQKS LSLSPGK DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLWISRTPEVTCWV DVEHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTP WPF-SELF LHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKGQPREPQVYTLP (M252W / V308P / N434F, PSRDELTKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKTTPP 12 S267E / L328F) VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHFHYTQKS LSLSPGK DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLWISRTPEVTCWV DVEHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTV WW-SELF LHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKGQPREPQVYTLP (M252W / N434W, PSRDELTKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKTTPP 13 S267E / L328F) VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHWHYTQKS LSLSPGK DKTHTCPPCPAPELLDGPSVFLFPPKPKDTLYITREPEVTCWV DVEHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTV YTEW-DE LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP (M252Y / S254T / T256E / N434W PSRDELTKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKTTPP 14 , G236D / S267E) VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHWHYTQKS LSLSPGK DKTHTCPPCPAPELLDGPSVFLFPPKPKDTLWISRTPEVTCWV DVEHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTP WPF-DE LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP (M252W / V308P / N434F, PSRDELTKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKTTPP 15 G236D / S267E) VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHFHYTQKS LSLSPGK DKTHTCPPCPAPELLDGPSVFLFPPKPKDTLYITREPEVTCWV DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTP YTEPY-GDLF LHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKGQPREPQVYTLP (M252Y / S254T / T256E / V308P / PSRDELTKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKTTPP 16 N434Y, G236D / L328F) VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHYHYTQKS LSLSPGK DKTHTCPPCPAPELL_GPSVFLFPPKPKDTLYITREPEVTCVW YTEPY-AGSE DVEHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTP (M252Y / S254T / T256E / V308P / LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP 17 N434Y, AG236 / S267E)PSRDELTKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHYHYTQKS LSLSPGK DKTHTCPPCPAPELLGDDSVFLFPPKPKDTLYITREPEVTCWV DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTV YTEW-GDPDLF LHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKGQPREPQVYTLP (M252Y / S254T / T256E / N434W PSRDELTKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKTTPP 18 , G237D / P238D / L328F) VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHWHYTQKS LSLSPGK DKTHTCPPCPAPELLDDDSVFLFPPKPKDTLYITREPEVTCWV YTEW-GDGDPDLF DVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTV (M252Y / S254T / T256E / N434W LHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKGQPREPQVYTLP PSRDELTKNQVSLTCLVKGFYPSD IAVEWESNGQPENNYKTTPP 19 G236D / G237D / P238D / L328F) VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHWHYTQKSLSLSPGK

[0262] Specifically, the affinity of the hFcRn antagonist for biotinylated hFcRn (Aero Biosystems, FCM-H82W7) was measured based on Bio-Layer Interferometry (BLI) using a OctetR8 (Satorius) system. The biotinylated hFcRn was diluted to 0.4 pg / mL in HBS-P buffer (0.01 M HEPES, 150 mM NaCl, 0.05% Tween 20, pH 6.0 and pH 7.4) and captured on streptavidin biosensors (Sartorius, 18-5019) for 300 s. Human IgGl (hlgGl) modified Fc fragments were evaluated at 50, 25, and 0 nM in pH 7.4 buffer, with 300 s association and 300 s dissociation phases, and at 10, 5 and 0 nM in buffer at pH 6.0. For analysis of the results, the biosensors used for the 0 nM measurements served as a reference. Kon and Kott values were calculated using a 1:1 binding model. The binding affinity (Kd) at pH 7.4 and pH 6.0 is shown in Table 5.

[0263] Recombinant human FcyRIlb (hFcyRUb) (R&D Systems, A VII 875) was diluted to 0.3 pg / mL in HBS-P buffer (pH 7.4) and captured on SA biosensors for 300 s. Samples (50, 25, and 0 nM) were then analyzed in HBS-P buffer with 300 s association and 120 s dissociation phases. For analysis of the results, the biosensors used for the 0 nM measurements served as a reference. Konand KOff values were calculated using a 1:1 binding model. The binding affinity (Kd) at pH 7.4 and pH 6.0 is shown in Table 5.Table 5. Binding affinity of the modified Fc fragments to hFcRn and hFcyRIIB.SEQ ID Kd (hFcRn) (M)Fc fragment Kd (hFcyRIIB) (M) NO: pH 7.4 pH 6.01 hlgGl Fc 1.05E-06 8.00E-09 1.30E-07 SELF2 >1. 2.20E-08 (S267E / L328F) 00E-06 >1.00E-06YTEPY3 (M252Y / S254T / T256E / V308P / 3.62E-10 1.64E-12 >1.00E-06 N434Y)YTEPY-SELF4 (M252Y / S254I7T256E / S267E / 7.46E-10 1.65E-12 1.47E-08V308P / L328F / N434Y)YTEKF-SELF5 (M252Y / S254T / T256E / H433K / N434 5.54E-10 2.85E-10 2.65E-08 F, S267E / L328F)6 YTE-SELF (M252Y / S254T / T256E, 1.77E-09 3.26E-10 1.36E-08 S267E / L328F)YTEW-SELF (7 M252Y / S254T / 1256E / N434W, 5.79E-10 9.00E-11 1.39E-08 S267E / L328F)YPY-SELF8 (M252Y / V308P / N434Y, 2.53E-10 1.53E-10 1.59E-08 S267E / L328F)YTEPF-SELF9 (M252Y / S254T / T256E / V308P / N434 5.80E-10 5.60E-11 2.15E-08 F, S267E / L328F)YTEPRY-SELF10 (M252Y / S254T / T256E / V308P / H433 3.10E-10 1.00E-12 1.02E-08 R / N434Y, S267E / L328F)WPRY-SELF11 (M252W / V308P / H433R / N434Y, 3.10E-10 9.60E-11 4.22E-09 S267E / L328F)WPF-SELF12 (M252W / V308P / N434F, 4.30E-10 1.00E-12 2.10E-09 S267E / L328F)YTEPY-GDLF,16 (M252Y / S254T / T256E / V308P / N434 3.20E-10 8.00E-12 2.02E-08 Y, G236D / L328F)YTEPY-AGSE17 (M252Y / S254T / T256E / V308P / N434 4.10E-10 1.00E-12 3.557E-09 Y, AG236 / S267E)YTEW-GDPDLF18 (M252Y / S254T / T256E / N434W, 8.00E-10 9.30E-11 3.96E-08 G237D / P238D / L328F)YTEW-GDGDPDLF19 (M252Y / S254T / T256E / N434W, 1.33E-09 3.50E-11 1.43E-08G236D / G237D / P238D / L328F)Example 2. Anti-IgAl antibody with modified Fc fragments

[0264] The exemplary molecules comes from the heavy chain and light chain variable regions of an anti-IgAl mouse antibody, HISA43, which is an anti-human IgA monoclonal antibody that specifically recognizes and binds to an epitope located within the Fc region of human IgAl (hlgAl). The mouse Fc region of HISA43 was replaced with a human IgGl (hlgGl) Fc region, into which specific Fc mutations are introduced to enhance the binding affinity of the Fc domains to human FcRn and FcyRIIB. A monovalent HISA43 antibody was constructed to have a modified Fc dimerized utilizing a 'knob-into-hole' (KiH) structure to facilitate specific heavy chain heterodimerization.

[0265] Constructs with the modified Fc domain and HISA43 antibody are generated and illustrated in Table 6.Table 6. Sequences of HISA43 with the modified Fc fragmentsSEQChain Amino acid sequence ID NO:HISA-hlgGl Fc EVQLQQSGPELVKPGASMKISCKASGYSFTGYTMNWVKQSHGKNLEWIGLIN (WT) Heavy PYNGGTTYNPKIKGKATLFVDKSSSTAYMDLLSLTSEDSAVYYCARSVGYQP Chain Variable LVSMDYWGQGTSVTVSS 81 RegionHISA43 antibody QIVLTQSPAIMSASPGEKVTMTCSASSSVNYMHWYQQKSGTSPKRWIYDTSK Light Chain LASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSNNPYTFGGGTKLE 82 Variable Region IKHISA43 QIVLTQSPAIMSASPGEKVTMTCSASSSVNYMHWYQQKSGTSPKRWIYDTSK antibody LASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSNNPYTFGGGTKLE Light LC IKRTVAAPSVFIFPPSDEQLKSGTASWCLLNNFYPREAKVQWKVDNALQSG 37 Chain NSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF NRGEC EVQLQQSGPELVKPGASMKISCKASGYSFTGYTMNWVKQSHGKNLEWIGLIN PYNGGTTYNPKIKGKATLFVDKSSSTAYMDLLSLTSEDSAVYYCARSVGYQP LVSMDYWGQGTSVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHT FPAVLQSSGLYSLSSWTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD HISA- HC1 KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEV 38 hlgGl Fc KFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSN (WT) KALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSDI Heavy AVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH Chain EALHNHYTQKSLSLSPGK DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCWVDVSHEDPE VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS HC2 NKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSD 39 IAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVM HEALHNHYTQKSLSLSPGK EVQLQQSGPELVKPGASMKISCKASGYSFTGYTMNWVKQSHGKNLEWIGLIN PYNGGTTYNPKIKGKATLFVDKSSSTAYMDLLSLTSEDSAVYYCARSVGYQP LVSMDYWGQGTSVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHT HISA43- FPAVLQSSGLYSLSSWTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD IIC1 KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVWDVEHEDPEV 40 hlgGl FcHeavy KFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSN Chain KAFPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSDI ‘■SELF” AVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH (S267E / L EALHNHYTQKSLSLSPGK328F) DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCWVDVEHEDPE VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS HC2 NKAFPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSD 41 IAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVM HEALHNHYTQKSLSLSPGK EVQLQQSGPELVKPGASMKISCKASGYSFTGYTMNWVKQSHGKNLEWIGLIN HISA43- PYNGGTTYNPKIKGKATLFVDKSSSTAYMDLLSLTSEDSAVYYCARSVGYQP hlgGl Fc LVSMDYWGQGTSVTVSSHeavy ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHT Chain FPAVLQSSGLYSLSSWTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD ‘■YTEPY” HC1 KTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCWVDVSHEDPEV 42 (M252Y / S KFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTPLHQDWLNGKEYKCKVSN 254T / T25 KALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSDI 6E / V308P AVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH / N434Y)EALHYHYTQKSLSLSPGKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVWDVSHEDPE VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTPLHQDWLNGKEYKCKVS HC2 NKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSD 43 IAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVM HEALHYHYTQKSLSLSPGK EVQLQQSGPELVKPGASMKISCKASGYSFTGYTMNWVKQSHGKNLEWIGLIN HISA43- PYNGGTTYNPKIKGKATLFVDKSSSTAYMDLLSLTSEDSAVYYCARSVGYQPhlgGl Fc LVSMDYWGQGTSVTVSSHeavyASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTChain FPAVLQSSGLYSLSSWTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD "Y'l El’Y- HC1 KTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCWVDVEHEDPEV 44 SELF” KFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTPLHQDWLNGKEYKCKVSN (M252Y / S KAFPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSDI 254T / T25 AVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH 6E / S267E EALHYHYTQKSLSLSPGK / DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVWDVEHEDPE V308P / L3 VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTPLHQDWLNGKEYKCKVS 28F / HC2 NKAFPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSD 45 N434Y) IAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVM HEALHYHYTQKSLSLSPGK EVQLQQSGPELVKPGASMKISCKASGYSFTGYTMNWVKQSHGKNLEWIGLIN PYNGGTTYNPKIKGKATLFVDKSSSTAYMDLLSLTSEDSAVYYCARSVGYQP HISA43- LVSMDYWGQGTSVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHThlgGl FcHeavy FPAVLQSSGLYSLSSWTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD HC1 KTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCWVDVSHEDPEV 46 ChainKFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSN KALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSDI“YTEKF” AVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH (M252Y / S EALKFHYTQKSLSLSPGK254T / T25 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVWDVSHEDPE 6E / H433 VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS K / N434F) HC2 NKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSD 47IAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVM HEALKFHYTQKSLSLSPGK EVQLQQSGPELVKPGASMKISCKASGYSFTGYTMNWVKQSHGKNLEWIGLIN HISA43- PYNGGTTYNPKIKGKATLFVDKSSSTAYMDLLSLTSEDSAVYYCARSVGYQP hlgGl Fc LVSMDYWGQGTSVTVSSHeavy ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHT Chain FPAVLQSSGLYSLSSWTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD HC1 KTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCWVDVEHEDPEV 48 “YTEKF- KFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSN SELF” KAFPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSDI (M252Y / S AVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH 254T / T25 EALKFHYTQKSLSLSPGK6E / H433 DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVWDVEHEDPE K / N434F VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVS S267E / L3 HC2 NKAFPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSD 49 28F) IAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALKFHYTQKSLSLSPGK

[0266] The internalization ability of the monovalent HISA43 antibodies having modified Fc domain to facilitate FcRn- and / or FcyRIIB -mediated internalization of hlgAl was evaluated using CHO-K1 cells stably expressing human FcRn (CHO-Kl / hFcRn) and CHO-K1 cells stably expressing human FcyRIIB (CHO-Kl / hFcyRIIB). hlgAl was conjugated to a pH-sensitive fluorophore (pHrodo Deep Red; Invitrogen, P35357) to enable detection of internalization under acidic intracellular conditions.

[0267] pHrodo-labeled hlgAl (final concentration 11 nM) and the HISA43 antibody (final concentration 10 and 50 nM) were added to the cells. Following an 1-hour incubation at 37 °C in the dark, cells were washed, fixed, and analyzed by flow cytometry using an Agilent NovoCyte 3000 via the APC channel. Mean fluorescence intensity (MFI) values were quantified using FlowJo software to assess internalization of hlgAl.

[0268] FIGs. 1A-B show the results of the flow cytometry MFI values, comparing the hlgAl internalization properties of HISA43 with modified Fc fragments in CHO-Kl / FcRn cells (FIG.1A) and CHO-Kl-FcyRIIB cells (FIG. IB). As shown in FIG. 1A, relative to the HISA43 with human IgGl wild-type (WT) Fc control, the HISA43 with YTEPY-SELF and YTEKF-SELF modified Fc exhibited approximately 14-fold higher MFI, in CHO-Kl / hFcRn cells. Also, as shown in FIG. IB, relative to the HISA43 with human IgGl wild-type (WT) Fc control, the HISA43 with YTEPY-SELF and YTEKF-SELF modified Fc exhibited approximately 4.5-fold and 7.5-fold higher MFI, respectively, in CHO-Kl / hFcyRIIB cells.

[0269] Next, the ability of HIS A43 antibody with YTEKF-SELF modified Fc to inhibit activation of primary human B cells was evaluated using a B cell inhibition assay, conducted substantially in accordance with the method described by Chu et al. (Chu SY et al. Inhibition of B cell receptor- mediated activation of primary human B cells by coengagement of CD 19 and FcgammaRIIb with Fc-engineered antibodies. Mol. Immunol. 2008 Sep;45(15):3926-33). Specifically, human peripheral blood mononuclear cells (PBMCs) were isolated from fresh human leukopak (Stemcell Technologies, 70500.2) by density gradient centrifugation using FicolLPaque PLUS (Cytiva, 17144002). B cells were subsequently isolated from PBMCs by negative selection using a magnetic separation-based human B cell isolation kit (StemCell Technologies, 100-0971). Isolated B cells were plated at a density of IxlO5cells per well and stimulated with an anti-CD79b antibody (Santa cruz, SC- 18902) to induce B cell receptor (BCR)-mediated activation. HISA43 antibodies with modified Fc were added at varying concentrations, and cells were incubated for approximately 20-24 hours at 37 °C.

[0270] Following incubation, cells were washed and stained with a fluorescently labeled antihuman IgA antibody (Miltenyi Biotech, 130-113-472) to detect surface-bound IgA, and withAnnexin V (Biolegend, 640924) and propidium iodide (Biolegend, 421301) to assess apoptosis. Stained cells were analyzed by flow cytometry using a NovoCyte 3000 flow cytometer. B cell apoptosis or inhibition was assessed based on Annexin V positive and PI negative populations. The results of the B cell inhibition assay is shown in FIGs.2A-B. FIG. 2A shows IgA+B cells while FIG. 2B shows overall B cell population.

[0271] As shown in FIG. 2A, treatment with HISA43 having YTEKF-SELF modified Fc treatment resulted in increased apoptosis of IgA+B cells compared to control antibodies, by FcyRIIB and BCR (IgA) co-ligation. On the other hand, there was no observed effect on the overall B cell population as shown in FIG. 2B.

[0272] The in vivo activity of HISA43 antibodies with modified Fc was evaluated in hCD89 / hIgAl knock-in mice (Strain # T057918; GemPharmatech), which express human IgA and the human CD89 receptor. The HISA43 antibodies were administered intravenously at a dose of 10 mg / kg on day 0. Serum human IgA levels were measured by ELISA at predetermined time points. For each animal, the pre-dose serum hlgA level was set to 100%, and the remaining hlgA level at each post-dose time point was calculated relative to the predose level. The results are shown in FIG. 3. FIG. 3 shows the average hlgAl profiles in serum upon IV administration of HISA43 with modified Fc fragments. hCD89 / hIgAl knock-in mice were included per group in the analysis is indicated with (n=5) and data is depicted as mean ± SD.

[0273] As shown in FIG. 3, at 6 hours after administration of HISA43 antibodies comprising various Fc variants, a decrease in serum hlgA was observed. Specifically, HISA43 antibodies with the YTEKF-SELF and YTEPY-SELF Fc variants, which exhibit increased binding affinity to FcRn and FcyRIIB, showed greater reduction of serum hlgA as compared to Fc variants having increased binding affinity to FcRn or FcyRIIB alone.Example 3. BP180 fusion protein with modified Fc fragments

[0274] A monovalent BP 180 fusion protein is formed with truncated NC16A fragment (comprising amino acids 514-566) or full-length NC16A (comprising amino acids 490-566) of human BP 180, fused to the C-terminus of a human IgGl (hlgGl) modified Fc fragment via a flexible (G4S)3 linker. To ensure specific heavy chain heterodimerization, this construct was then dimerized with a corresponding Fc partner utilizing a 'knob-into-hole' (KiH) architecture.To enhance construct stability, additional amino acid substitutions R292C and V302C were introduced into the Fc region to form an intradomain disulfide bond within the CH2 domain. Sequences of the fusion proteins are shown in Table 7.Table 7. Sequences of the modified Fc domain or the hNC16A fusion proteinChain Amino acid sequence SEQ ID NO:Truncated hNC16A DSMDRIEKDRLQGMAPAAGADLDKIGLHSDSQEELWMFVR(aa 514-566 of human KKLMMEQENGNLR 50 BP180)hNC16A (aa 490-566 EEVRKLKARVDELERIRRSILPYGDSMDRIEKDRLQGMAP AAGADLDKIGLHSDSQEELWMFVRKKLMMEQENGNLR 83 of human BP180)DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT CVWDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSDIAVE HC1 WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG 51 Truncated hNC16A- NVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGG hlgGl Fc Heavy GSDSMDRIEKDRLQGMAPAAGADLDKIGLHSDSQEELWMF Chain, VRKKLMMEQENGNLRhlgGl Fc (WT) DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK HC2 GQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSDIAVE 52 WESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLWISRTPEVT CVVVDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTY RCVSVLTPLHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKTruncated hNC16A- GQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSDIAVEHC1 WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG 53 hlgGl Fc HeavyChain, NVFSCSVMHEALHFHYTQKSLSLSPGKGGGGSGGGGSGGG “WPF-SELF” ”+ “CC GSEEVRKLKARVDELERIRRS ILPYGDSMDRIEKDRLQGM mutant” APAAGADLDKIGLHSDSQEELWMFVRKKLMMEQENGNLR M252W / S267E / R292C DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLWISRTPEVT / V302C / V308P / L328F / CVVVDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTY N434F RCVSVLTPLHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKHC2 GQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSDIAVE 54 WESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQG NVFSCSVMHEALHFHYTQKSLSLSPGK DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVT CVVVDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTY RCVSVLTPLHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKTruncated hNC16A- GQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSDIAVEnet WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG 55 hlgGl Fc HeavyChain, NVFSCSVMHEALHYHYTQKSLSLSPGKGGGGSGGGGSGGG “YTEPY-SELF”+ “CC GSEEVRKLKARVDELERIRRS ILPYGDSMDRIEKDRLQGM mutant” APAAGADLDKIGLHSDSQEELWMFVRKKLMMEQENGNLR M252Y / S254T / T256E / DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVT S267E / R292C / V302C / CVVVDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTY V308P / L328F / N434Y RCVSVLTPLHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKHC2 GQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSDIAVE 56 WESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHYHYTQKSLSLSPGKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVT CVVVDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTY RCVSVLTVLHQDWLNGKEYKCKVSNKAFPAP IEKTISKAKTruncated hNC16A- GQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSDIAVE hTgGl Fc Heavy HC1 WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG 57 Chain, NVFSCSVMHEALHWHYTQKSLSLSPGKGGGGSGGGGSGGG “YTEW-SELF” + ''CC GSEEVRKLKARVDELERIRRS ILPYGDSMDRIEKDRLQGM mutant” APAAGADLDKIGLHSDSQEELWMFVRKKLMMEQENGNLR M252Y / S254T / T256EZ DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVT S267E / R292C / V302C / CVVVDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTY L328F / N434W RCVSVLTVLHQDWLNGKEYKCKVSNKAFPAP IEKTISKAK HC2 GQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSDIAVE 58 WESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQG NVFSCSVMHEALHWHYTQKSLSLSPGK DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYISRTPEVT CVVVDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTY RCVSVLTPLHQDWLNGKEYKCKVSNKAFPAP IEKTISKAKTruncated hNC16A- GQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSDIAVE hlgGl Fc Heavy HC1 WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG 59 Chain, NVFSCSVMHEALHYHYTQKSLSLSPGKGGGGSGGGGSGGG “YPY-SELF”+ “CC GSEEVRKLKARVDELERIRRS ILPYGDSMDRIEKDRLQGM mutant” APAAGADLDKIGLHSDSQEELWMFVRKKLMMEQENGNLR M252Y / S267E / DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYISRTPEVT R292C / V302C / CVVVDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTY V308P / N434Y / L328F RCVSVLTPLHQDWLNGKEYKCKVSNKAFPAP IEKTISKAK HC2 GQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSDIAVE 60 WESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQG NVFSCSVMHEALHYHYTQKSLSLSPGK DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVT CVVVDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTYTruncated 11NC16A- RCVSVLTPLHQDWLNGKEYKCKVSNKAFPAP IEKTISKAK GQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSDIAVEhlgGl Fc Heavy HC1 WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG 61 Chain,NVFSCSVMHEALRYHYTQKSLSLSPGKGGGGSGGGGSGGG“YTEPRY-SELF”+ GSEEVRKLKARVDELERIRRS ILPYGDSMDRIEKDRLQGM “CC mutant” APAAGADLDKIGLHSDSQEELWMFVRKKLMMEQENGNLR M252Y / S254T / T256E / DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVT S267E / CVVVDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTY R292C / V302C / V308P / RCVSVLTPLHQDWLNGKEYKCKVSNKAFPAP IEKTISKAK L328F / H433R / N434Y HC2 GQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSDIAVE 62WESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQG NVFSCSVMHEALRYHYTQKSLSLSPGK DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLWISRTPEVT CVVVDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTY RCVSVLTPLHQDWLNGKEYKCKVSNKAFPAP IEKTISKAKTruncated hNC16A- GQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSDIAVE hlgGl Fc Heavy HC1 WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG 63 Chain, NVFSCSVMHEALRYHYTQKSLSLSPGKGGGGSGGGGSGGG “WPRY-SELF” +“CC GSEEVRKLKARVDELERIRRS ILPYGDSMDRIEKDRLQGM mutant” APAAGADLDKIGLHSDSQEELWMFVRKKLMMEQENGNLR M252W / S267E / DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLWISRTPEVT R292C / V302C / CVVVDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTY V3O8P / L328F / RCVSVLTPLHQDWLNGKEYKCKVSNKAFPAP IEKTISKAK H433R / N434Y HC2 GQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSDIAVE 64WESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALRYHYTQKSLSLSPGKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT CWVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR’7VSVLTVLHQDWLNGKEYKCKVSNK.ALPAPIEKTI3KAFt GQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSDIAVE HC1 84 WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGhNC16A-h!gGl Fc GSEEVRKLKARVDELERIRRSILPYGDSMDRIEKDRLQGM Heavy chain, hlgGl FcAPAAGADLDKIGLHSDSQEELWMFVRKKLMMEQENGNLR(WT)DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT CVWDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK HC2 85 GQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLWISRTPEVT CVVVDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTY RCVSVLTPLHQDWLNGKEYKCKVSNKATPAPIEKTISKAK GQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSDIAVEhNC16A- hlgGl Fc HC1 86WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGHeavy Chain,NVFSCSVMHEALHFHYTQKSLSLSPGKGGGGSGGGGSGGG“WPF-SELF” ”+ “CCGSEEVRKLKARVDELERIRRSILPYGDSMDRIEKDRLQGMmutant”APAAGADLDKIGLHSDSQEELWMFVRKKLMMEQENGNLRM252W / S267E / R292C DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLWISRTPEVT / V302C / V308P / L328F / CVVVDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTY N434F RCVSVLTTLHQDWLNGKEYKCKVSNKAyPAPIEKTISKAK HC2 87 GQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSDIAVE WESMGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQG NVFSCSVMHEALHFHYTQKSLSLSPGK DKTHTCFPCPAPELLGGPSVFLFFPKPKDTLYITREPEVT CVVVDVEHEDPEVKFNWYVEGVEVHNAKTKPCEEQYNSTY RCVSVLTPLHQDWLNGKEYKCKVSNKATPAPIEKTISKAK GQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSDIAVEhNC16A- hlgGl Fc HC1 IflESNGQPENMYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG 88 Heavy Chain,WFSCSVMHEALHYHYTQKSLSLSPGKGGGGSGGGGSGGG“YTEPY SELF”+ “CC GSEEVRKLKARVDELERIRRSILPYGDSMDRIEKDRLQGM mutant” APAAGADLDKIGLHSDSQEELWMFVRKKLMMEQENGNLR M252Y / S254T / T256E / DKTHTCPPCP AP E L LG G P SVF LF P P KP KD T L Y I TREP E VT S267E / R292C / V302C / CVVVDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTY V3O8P / L328F / N434Y RCVSVLTPLHQDWLNGKEYKCKVSNKAFPAPIEKilSKAK HC2 89 GQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQG NVFSCSVMHEALHYHYTQKSLSLSPGK DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVT CVWDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTY RCVSVLTVLHQDWLNGKEYKCKVSNKAFPAPIEKTISKAK GOPREPQVYTLPPSRDELTKNOVSLWCLVKGFYPSOIAVEhNC16A- hlgGl Fc HC1 90WESNGQPEWYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGHeavy Chain, NVFSCSVMI-IEALHWHYTQKSLSLSPGKGGGGSGGGGSGGG “YTEW-SELF” + “CCGSEEVRKLKARVDELERIRRSILPYGDSMDRIEKDRLQGMmutant” APAAGADLDKIGLHSDSQEELWMFVRKKLMMEQENGNLR M252Y / S254T / T256E / DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVT S267E / R292C / V302C / CVVVDVEHEDPEVKFNWY VRGVEVHNAKTKPCEEQYNSTY L328F / N434W RCVSVLWLHQDWLNGKEYKCKVSNICAFPAPIEKTISKAK HC2 91 GQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHFHYTQKSLSLSPGKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYISRTPEVT CVVVDVEHEDPEVKFNiVYVDGVEVHNAKTKPCEEQYNSTY RCVSVLTTLHQDWLNGKEYKCKVSNKAFPAPIEKTISKAK GQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSDIAVE11NC16A- hlgGl Fc HC1 92 WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGHeavy Chain, NVFSCSVMHEALHYHYTQKSLSLSPGKGGGGSGGGGSGGG”YPY-SELF”+ “CCGSEEVRKLKARVDELERIRRS ILPYGDSMDRIEKDRLQGMmutant”APAAGADLDKIGLHSDSQEELWMFVRKKLMMEQENGNLRM252Y / S267E / DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYISRTPEVTR292C / V302C / CVWDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTY V308P / N434Y / L328F RCVSVLTPLHQDWLNGKEYKCKVSNKAYPAPIEKTISKAKHC2 93 GQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQG NVFSCSVMHEALRYHYTQKSLSLSPGK DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVT CVVVDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTY RCVSVLTPLHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKhNC16A- hlgGl Fc GQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSDIAVEHeavy Chain, HC1 WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG 94 “YTEPRY-SELF”+ NVFSCSVMHEALRYHYTQKSLSLSPGKGGGGSGGGGSGGG”CC mutant” GSEEVRKLKARVDELERIRRS ILPYGDSMDRIEKDRLQGM M252Y / S254T / T256E / APAAGADLDKIGLHSDSQEELWMFVRKKLMMEQENGNLRS267E / DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVT R292C / V302C / V308P / CVVVDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTYL328F7 H433R / N434Y RCVSVLTPLHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKHC2 GQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSDIAVE 95 WESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQG NVFSCSVMHEALRYHYTQKSLSLSPGK DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLWISRTPEVT CVVVDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTY RCVSVLTPLHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKhNC16A- hlgGl Fc GQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSDIAVEHC1 WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG 96 Heavy Chain,“WPRY-SELF” +"CC NVFSCSVMHEALRYHYTQKSLSLSPGKGGGGSGGGGSGGG mutant” GSEEVRKLKARVDELERIRRS ILPYGDSMDRIEKDRLQGM M252W / S267E / APAAGADLDKIGLHSDSQEELWMFVRKKLMMEQENGNLR R292C / V302C / DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLWISRTPEVT V308P / L328F / CVVVDVEHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTY H433R / N434Y RCVSVLTPLHQDWLNGKEYKCKVSNKAFPAPIEKTISKAKHC2 GQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSDIAVE 97 WESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALRYHYTQKSLSLSPGK

[0275] A cell-based binding assay was performed to evaluate NC16A-Fc fusion constructs engineered to enhance binding to human FcRn and FcyRIIB. CIIO-Kd / FcRn cells (GenScript, M00603) and CHO-Kl / FcyRIIB cells (ECACC, 15042907) were suspended in PBS containing 2% fetal bovine serum (FBS) and plated in 96-well plates at 1 x HF cells per well. Biotinylated test articles were added to a final concentration of 50 nM and incubated for 20 minutes at 4°C in the dark. After washing, streptavidin (SA)-APC (BioLegend, 420801) was added and incubated for an additional 20 minutes at 4°C. Cells were then washed, fixed, and analyzed by flow cytometry (Agilent NovoCyte® 3000) using the APC channel.

[0276] Mean fluorescence intensity (MFI) was quantified using FlowJo software to determine binding to hFcRn and hFcyRIIB. The results of a flow cytometry experiment is shown in FIGs.4A-B. FIGs. 4A-B show the hFcRn and hFcyRIIB binding properties of full-length hNC16A-Fc fusion constmcts in CHO-Kl / FcRn cells (FIG.4A) and CHO-Kl-FcyRIIB cells (FIG. 4B). MFI values were normalized to the human IgGl Fc construct (set to 1), and relative binding was calculated for each construct. As shown in FIGs. 4A-B, hNC16A-Fc fusion protein constructs with enhanced FcRn and FcyRIIB binding exhibited at least a 100-fold increase in MFI in CHO-Kl / FcRn cells and greater than a 2-fold increase in CHO-Kl / FcyRIIB cells compared with hlgG WT, demonstrating substantially increased binding.

[0277] Next, the in vivo efficacy of NC16A-Fc fusion constructs was evaluated in Tg32 mice (Strain #014565, The Jackson laboratory), which endogenously express human FcRn.Biotinylated tracer antibody (anti-COL17 / NC16a-3 mouse monoclonal antibody, MediMab, MM-0065P) was administered intravenously at a dose of 5 mg / kg two hours (-2 hr) prior to dosing with test articles on day 0. Truncated hNC16A-Fc fusion constructs were administered intravenously at a dose of 10 mg / kg on day 0. Serum levels of the biotinylated tracer antibody were measured by ELISA at predetermined time points. Serum levels of remaining Tracer antibody (%) at 6hr post-dose and half-life of tracer antibodies are shown in Table 8. The tracer antibody half-life was calculated from the 0-6 hour interval, and pharmacokinetic parameters, including terminal half-life, were determined using Phoenix WinNonLin (version 6.3 or higher).Table 8. Pharmacokinetics of Tracer antibody after the NC16A-Fc fusion construct administration in Tg32 mice.Target-Fusion construct, Remaining Tracer Ab (%) Tracer Ab, T1 / 2Described fc mutation at 6hr post-dose (hr)PBS -4E5 9.29hlgG WT -66.6 4.55YPY SELF / CC -94.6 1.55YTEW-SELF / CC -94.1 1.59WPF-SELF / CC -97.1 1.31YTEPRY-SELF / CC -97.3 1.27

[0278] As shown in Table 8, the truncated hNC16A-Fc fusion constructs with increased binding affinity to FcRn and FcyRIIB were compared with fusion constructs comprising wildtype IgGl Fc domain. In the PBS (control) group, in which only the tracer antibody was administrated, the tracer exhibited a terminal half-life of 9.29 hours. Administration of NC16A-Fc fusion construct capable of capturing the tracer antibody accelerated its clearance. A wildtype IgGl Fc fusion construct reduced the half-life of the tracer antibody to 4.55 hours, whereas NC16A-Fc fusion constructs incorporating Fc mutations that enhance FcRn and FcyRIIB binding shorten the tracer half-life to <2 hours. By 6 hours post-dose, more than 90% of circulating tracer antibody was eliminated.* * *

[0279] The present disclosure is not to be limited in scope by the specific embodiments described which are intended as single illustrations of individual aspects of the disclosure, and any compositions or methods which are functionally equivalent are within the scope of this disclosure. It will be apparent to those skilled in the art that various modifications and variations can be made in the methods and compositions of the present disclosure without departing from the spirit or scope of the disclosure. Thus, it is intended that the present disclosure cover the modifications and variations of this disclosure provided they come within the scope of the appended claims and their equivalents.

[0280] All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

Claims

1. CLAIMSWhat is claimed is:

1. A modified Fc domain that has increased binding affinity to FcRn and FcyRIIB as compared to wild type Fc domain.

2. The modified Fc domain of claim 1, comprising one or more amino acid mutations selected from the group consisting of:(i) an aspartic acid (D) substitution or amino acid deletion at amino acid position 236 (236D or A236),(ii) an aspartic acid (D) substitution at amino acid position 237 (237D), (iii) an aspartic acid (D) substitution at amino acid position 238 (238D), (iv) a tyrosine (Y),or a tryptophan (W) substitution at amino acid position 252 (252Y or 252W),(v) a threonine (T) substitution at amino acid position 254 (254T), (vi) a glutamic acid (E) substitution at amino acid position 256 (256E), (vii) a glutamic acid (E) substitution at amino acid position 267 (267E), (viii) a proline (P) substitution at amino acid position 308 (308P), (ix) a phenylalanine (F) substitution at amino acid position 328 (328F), (x) a lysine (K) or an arginine (R) substitution at amino acid position 433 (433K or 433R), and(xi) a tyrosine (Y), a tryptophan (W), a phenylalanine (F), or an arginine (R) substitution at amino acid position 434 (434Y, 434W, 434F, or 434R).

3. The modified Fc domain of claim 2, comprising:(a) one or more mutations selected from the group consisting of (i) 252Y or 252W, (ii) 254T, (iii) 256E, (iv) 308P, (v) 433K or 433R, and (vi) 434Y, 434W, 434F, or 434R; and(b) one or more mutations selected from the group consisting of (i) 236D or A236, (ii) 237D, (iii) 238D, (iv) 267E, (v) 308P, and (vi) 328F.

4. The modified Fc domain of any one of claims 1-3, wherein the modified Fc domain is derived from a human IgGl, IgG2, IgG3, or IgG4 Fc domain.

5. The modified Fc domain of claim 4, wherein the modified Fc domain is derived from a human IgGl Fc domain.

6. The modified Fc domain of any one of claims 1-5, comprising a set of mutations selected from the group consisting of,(i) M252Y / S254T / T256E / V308P / N434Y;(ii) M252Y / S254T / T256E / H433K / N434F;(iii) M252Y / S254T / T256E;(iv) M252Y / S254T / T256E / N434W;(v) M252Y / V308P / N434Y;(vi) M252Y / S254T / T256E / V308P / N434F;(vii) M252Y / S254T / T256E / V308P / H433R / N434Y;(viii) M252W / V308P / H433R / N434Y;(ix) M252W / V308P / N434F;(x) M252W / N434W;(xi) S267E / E328F;(xii) G236D / S267E;(xiii) G236D / L328F;(xiv) AG236 / S267E;(xv) G237D / P238D / L328F; and(xvi) G236D / G237D / P238D / L328F.

7. The modified Fc domain of any one of claims 1-6, comprising,(a) a first set of mutations selected from the group consisting of:(i)M252Y / S254T / T256E / V308P / N434Y;(ii) M252Y / S254T / T256E / H433K / N434F;(iii) M252Y / S254T / T256E;(iv) M252Y / S254T / T256E / N434W;(v) M252Y / V308P / N434Y;(vi) M252Y / S254T / T256E / V308P / N434F;(vii) M252Y / S254T / T256E / V308P / H433R / N434Y;(viii) M252W / V308P / II433R / N434Y;(ix) M252W / V308P / N434F; and(x) M252W / N434W; and(b) a second set of mutations selected from the group consisting of:(i) S267E / L328F;(ii) G236D / S267E;(iii) G236D / L328F;(iv) AG236 / S267E;(v) G237D / P238D / L328F; and(vi) G236D / G237D / P238D / L328F.

8. The modified Fc domain of any one of claims 1-6, comprising mutations selected from the group consisting of,(i) M252Y / S254T / T256E / V308P / N434Y and S267E / E328F;(ii) M252Y / S254T / T256E / H433K / N434F and S267E / L328F;(iii) M252Y / S254T / T256E and S267E / L328F;(iv) M252Y / S254T / T256E / N434W and S267E / L328F;(v) M252Y / V308P / N434Y and S267E / L328F;(vi) M252Y / S254T / T256E / V308P / N434F and S267E / L328F;(vii) M252Y / S254T / T256E / V308P / H433R / N434Y and S267E / L328F; (viii) M252W / V308P / H433R / N434Y and S267E / L328F;(ix) M252W / V308P / N434F and S267E / L328F;(x) M252W / N434W and S267E / L328F;(xi) M252Y / S254T / T256E / N434W and G236D / S267E;(xii) M252W / V308P / N434F and G236D / S267E;(xiii) M252Y / S254T / T256E / V308P / N434Y and G236D / L328F;(xiv) M252Y / S254T / T256E / V308P / N434Y and AG236 / S267E;(xv) M252Y / S254T / T256E / N434W and G237D / P238D / L328F: and (xvi) M252Y / S254T / T256E / N434W and G236D / G237D / P238D / L328F.

9. The modified Fc domain of any one of claims 1-8, comprising mutations of:(i) M252Y / S254T / T256E / V308P / N434Y and S267E / L328F; or (ii) M252Y / S254T / T256E / H433K / N434F and S267E / L328F.

10. The modified Fc domain of any one of claims 1-9, wherein the antibody lacks an asialoglycoprotein receptor (ASGPR)-binding moiety.

11. The modified Fc domain of any one of claims 1-10, further comprising one or more members selected from the group consisting of a leucine (L) at amino acid position 234, a leucine (L) at amino acid position 235, and a proline (P) at amino acid position 329.

12. The modified Fc domain of any one of claims 1-11, further comprising a phenylalanine (F) at position 243, a valine (V) at position 264, or both.

13. The modified Fc domain of any one of claims 1-12, further comprising one or more members selected from the group consisting of a threonine (T) at amino acid position 250, a methionine (M) at amino acid position 428, an asparagine (N) at amino acid position 434, and an asparagine (N) at amino acid position 325.

14. The modified Fc domain of any one of claims 1-13, comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 4-19 or a peptide having at least 80% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 4-19.

15. The modified Fc domain of any one of claims 1-13, comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 4-19 or a peptide having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 4-19.

16. The modified Fc domain of any one of claims 1-13, comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 4-19 or a peptide having at least 95% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 4-19.

17. The modified Fc domain of any one of claims 1-13, having an amino acid sequence selected from the group consisting of SEQ ID NOs: 4-19.

18. The modified Fc domain of any one of claims 1-17, wherein the modified Fc domain comprises at most 8 amino acid substitutions as compared to the wild-type Fc domain.

19. The modified Fc domain of any one of claims 1-18, wherein the modified Fc domain comprises at most 7 amino acid substitutions as compared to the wild-type Fc domain.

20. The modified Fc domain of any one of claims 1-1 , which is a heterodimer.

21. fhe modified Fc domain of claim 20, further comprising knob-into-hole mutations in its respective chains.

22. The modified Fc domain of claim 21, wherein the knob-into-hole mutations includes T366W in one chain, and T366S / L368A / Y407V in the other chain.

23. The modified Fc domain of claim 22, comprising the amino acid sequence pair of SEQ ID NOs: 68 / 45 or 70 / 49, or an amino acid sequence pair having at least 80% sequence identity to the amino acid sequence pair of SEQ ID NO: 68 / 45 or 70 / 49.

24. The modified Fc domain of any one of claims 1-23, further comprising R292C and V302C.

25. The modified Fc domain of any one of claims 1-24, comprising the amino acid sequence pair selected from the group consisting of SEQ ID NO: 71 / 54, 72 / 56, 73 / 58, 74 / 60, 75 / 62 and 76 / 64, or an amino acid sequence pair having at least 80% sequence identity to the amino acid sequence pair selected from the group consisting of SEQ ID NO: 71 / 54, 72 / 56, 73 / 58, 74 / 60, 75 / 62 and 76 / 64.

26. A modified Fc domain that has increased binding affinity to FcRn and FcyRIIB as compared to wild type Fc domain, wherein the modified Fc domain comprises:(i) a tyrosine (Y) substitution at amino acid position 252,(ii) a threonine (T) substitution at amino acid position 254,(iii) a glutamic acid (E) substitution at amino acid position 256,(iv) a lysine (K) substitution at amino acid position 433,(v) a phenylalanine (F) substitution at amino acid position 434,(vi) a glutamic acid (E) substitution at amino acid position 267,(vii) a phenylalanine (F) substitution at amino acid position 328, and(viii) a phenylalanine (F) at position 243, a valine (V) at position 264, or both, according to EU index as in Kabat.

27. The modified Fc domain of claim 26, wherein the modified Fc domain comprises a leucine (L) at amino acid position 234.

28. fhe modified Fc domain of claim 26 or 27, wherein the modified Fc domain comprises a leucine (L) at amino acid position 235.

29. The modified Fc domain of any one of claims 26-28, wherein the modified Fc domain comprises a proline (P) at amino acid position 329.

30. The modified Fc domain of any one of claims 26-29, wherein the modified Fc domain comprises a threonine (T) at amino acid position 250.

31. The modified Fc domain of any one of claims 26-30, wherein the modified Fc domain comprises a methionine (M) at amino acid position 428.

32. The modified Fc domain of any one of claims 26-31, wherein the modified Fc domain comprises an asparagine (N) at amino acid position 325.

33. The modified Fc domain of any one of claims 26-32, wherein the modified Fc domain comprises at most 8 amino acid substitutions as compared to the wild-type Fc domain.

34. The modified Fc domain of claim 33, wherein the modified Fc domain comprises at most 7 amino acid substitutions as compared to the wild-type Fc domain.

35. A modified Fc domain that has increased binding affinity to FcRn and FcyRIIB as compared to wild type Fc domain, wherein the modified Fc domain comprises:(i) a tyrosine (Y) substitution at amino acid position 252,(ii) a threonine (T) substitution at amino acid position 254, .(iii) a glutamic acid (E) substitution at amino acid position 256,(iv) a proline (P) substitution at amino acid position 308,(v) a tyrosine (Y) substitution at amino acid position 434; and(vi) a glutamic acid (E) substitution at amino acid position 267, and(vii) a phenylalanine (F) substitution at amino acid position 328.

36. The modified Fc domain of claim 35, wherein the modified Fc domain comprises one or more members selected from the group consisting of a leucine (L) at amino acid position 234, a leucine (L) at amino acid position 235, and a proline (P) at amino acid position 329.

37. Phe modified Fc domain of claim 35 or 36, wherein the modified Fc domain comprises one or more members selected from the group consisting of a threonine (T) at amino acid position 250, a methionine (M) at amino acid position 428, and an asparagine (N) at amino acid position 325.

38. The modified Fc domain of any one of claims 35-37, wherein the modified Fc domain comprises at most 8 amino acid substitutions as compared to the wild-type Fc domain.

39. The modified Fc domain of any one of claims 35-38, wherein the modified Fc domain comprises at most 7 amino acid substitutions as compared to the wild-type Fc domain.

40. A fusion protein comprising the modified Fc domain of any one of claims 1-39.

41. The fusion protein of claim 40, further comprising an antigen-binding domain fused to the modified Fc domain.

42. The fusion protein of claim 40, further comprising an autoantibody binding domain fused to the modified Fc domain.

43. The fusion protein of claim 42, wherein the autoantibody binding domain is fused to C-terminus of the modified Fc domain via a peptide linker.

44. The fusion protein of any one of claims 41-43, wherein the autoantibody binding domain has binding specificity to autoantibodies against NC16A region of human BP180.

45. The fusion protein of claim 44, wherein the autoantibody binding domain comprises the amino acid sequence of SEQ ID NO: 50 or 83.

46. The fusion protein of claim 45, further comprising a pair of first chain / second chain of the sequences selected from the group consisting of SEQ ID NOs: 53 / 54, 55 / 56, 57 / 58, 59 / 60, 61 / 62, 63 / 64, 84 / 85, 86 / 87, 88 / 89, 90 / 91, 92 / 93, 94 / 95, and 96 / 97.

47. The fusion protein of claim 45 or 46, wherein the autoantibody binding domain is fused to C-terminus of the modified Fc domain.

48. The fusion protein of claim 40, further comprising an autoantigen binding domain fused to the modified Fc domain.

49. fhe fusion protein of claim 48, wherein the autoantigen binding domain is fused to C-terminus of the modified Fc domain via a peptide linker.

50. The fusion protein of claim 42, wherein the autoantibody binding domain has binding specificity to the Fc region of human IgAl (hlgAl).

51. The fusion protein of claim 50, comprising a heavy chain variable region (VH) having the sequence of SEQ ID NO: 81 and a light chain variable region (VE) having the sequence of SEQ ID NO: 82.

52. The fusion protein of claim 50 or 51, comprising a combination of light chain / first heavy chain / second heavy chain of the sequence of SEQ ID NO: 37 / 44 / 45 or 37 / 48 / 49.

53. The fusion protein of claim 52, comprising the combination of light chain / first heavy chain / second heavy chain of the sequence of SEQ ID NO: 37 / 44 / 45.

54. An antibody that specifically binds to human IgAl (hlgAl), wherein the antibody comprises:a heavy chain variable region comprising:a heavy chain complementarity determining region 1 (CDRH1) of the heavy chain variable region having polypeptide sequence as set forth in SEQ ID NO: 81;a heavy chain complementarity determining region 1 (CDRH2) of the heavy chain variable region having polypeptide sequence as set forth in SEQ ID NO: 81; anda heavy chain complementarity determining region 1 (CDRII3) of the heavy chain variable region having polypeptide sequence as set forth in SEQ ID NO: 81; anda light chain variable region comprising:a light chain complementarity determining region 1 (CDRL1) of the light chain variable region having polypeptide sequence as set forth in SEQ ID NO: 82;a light chain complementarity determining region 1 (CDRL2) of the light chain variable region having polypeptide sequence as set forth in SEQ ID NO: 82; anda light chain complementarity determining region 1 (CDRL3) of the light chain variable region having polypeptide sequence as set forth in SEQ ID NO: 82; anda modified Fc domain that has increased binding affinity to FcRn and FcyRIIB as compared to wild type Fc domain, wherein the modified Fc domain comprises:(i) a tyrosine (Y) substitution at amino acid position 252,(ii) a threonine (T) substitution at amino acid position 254,(iii) a glutamic acid (E) substitution at amino acid position 256, (iv) a lysine (K) substitution at amino acid position 433,(v) a phenylalanine (F) substitution at amino acid position 434;( vi) a glutamic acid (E) substitution at amino acid position 267, and (vii) a phenylalanine (F) substitution at amino acid position 328.

55. The antibody of claim 54, comprising a heavy chain variable region (VH) that comprises the amino acid sequence of SEQ ID NO: 81, and a light chain variable region (VL) that comprises the amino acid sequence of SEQ ID NO: 82.

56. The antibody of claim 54 or 55, wherein the antibody lacks an asialoglycoprotein receptor (AS GPR) -binding moiety.

57. The antibody of any one of claims 54-56, wherein the modified Fc domain comprises one or more members selected from the group consisting of a leucine (L) at amino acid position 234, a leucine (L) at amino acid position 235, and a proline (P) at amino acid position 329.

58. The antibody of any one of claims 54-57, wherein the modified Fc domain comprises a phenylalanine (F) at position 243, a valine (V) at position 264, or both.

59. The antibody of any one of claims 54-58, wherein the modified Fc domain comprises one or more members selected from the group consisting of a threonine (T) at amino acid position 250, a methionine (M) at amino acid position 428, an asparagine (N) at amino acid position 434, and an asparagine (N) at amino acid position 325.

60. The antibody of any one of claims 54-59, wherein the modified Fc domain comprises at most 8 amino acid substitutions as compared to the wild-type Fc domain.

61. The antibody of any one of claims 54-60, wherein the modified Fc domain comprises at most 7 amino acid substitutions as compared to the wild-type Fc domain.

62. An antibody that specifically binds to human IgAl (hlgAl), wherein the antibody comprises:a heavy chain variable region comprising:a heavy chain complementarity determining region 1 (CDRH1) of the heavy chain variable region having polypeptide sequence as set forth in SEQ ID NO: 81;a heavy chain complementarity determining region 1 (CDRH2) of the heavy chain variable region having polypeptide sequence as set forth in SEQ ID NO: 81; anda heavy chain complementarity determining region 1 (CDRH3) of the heavy chain variable region having polypeptide sequence as set forth in SEQ ID NO: 81; anda light chain variable region comprising:a light chain complementarity determining region 1 (CDRL1) of the light chain variable region having polypeptide sequence as set forth in SEQ ID NO: 82;a light chain complementarity determining region 1 (CDRL2) of the light chain variable region having polypeptide sequence as set forth in SEQ ID NO: 82; anda light chain complementarity determining region 1 (CDRL3) of the light chain variable region having polypeptide sequence as set forth in SEQ ID NO: 82; anda modified Fc domain that has increased binding affinity to FcRn and FcyRIIB as compared to wild type Fc domain, wherein the modified Fc domain comprises:(i) a tyrosine (Y) substitution at amino acid position 252,(ii) a threonine (T) substitution at amino acid position 254, .(iii) a glutamic acid (E) substitution at amino acid position 256, (iv) a proline (P) substitution at amino acid position 308,(v) a tyrosine (Y) substitution at amino acid position 434;(vi) a glutamic acid (E) substitution at amino acid position 267, and (vii) a phenylalanine (F) substitution at amino acid position 328.

63. The antibody of claim 62, comprising a heavy chain variable region (VH) that comprises the amino acid sequence of SEQ ID NO: 81, and a light chain variable region (VL) that comprises the amino acid sequence of SEQ ID NO: 82.

64. The antibody of claim 62 or 63, wherein the antibody lacks an asialoglycoprotein receptor (AS GPR) -binding moiety.

65. The antibody of any one of claims 54-64, wherein the modified Fc domain comprises one or more members selected from the group consisting of a leucine (L) at amino acid position 234, a leucine (L) at amino acid position 235, and a proline (P) at amino acid position 329.

66. The antibody of any one of claims 62-65, wherein the modified Fc domain comprises a phenylalanine (F) at position 243. a valine (V) at position 264, or both.

67. The antibody of any one of claims 62-66, wherein the modified Fc domain comprises one or more members selected from the group consisting of a threonine (T) at aminoacid position 250, a methionine (M) at amino acid position 428, an asparagine (N) at amino acid position 434, and an asparagine (N) at amino acid position 325.

68. The antibody of any one of claims 62-67, wherein the modified Fc domain comprises at most 8 amino acid substitutions as compared to the wild-type Fc domain.

69. The antibody of any one of claims 62-68, wherein the modified Fc domain comprises at most 7 amino acid substitutions as compared to the wild-type Fc domain.

70. A fusion protein that specifically binds to autoantibodies against NC16A region of human BP180, wherein the fusion protein comprises:an autoantibody binding region comprising the amino acid sequence of SEQ ID NO: 50; anda modified Fc domain that has increased binding affinity to FcRn and FcyRIIB as compared to wild type Fc domain, wherein the modified Fc domain comprises:(i) a tyrosine (Y) substitution at amino acid position 252,(ii) a threonine (T) substitution at amino acid position 254, .(iii) a glutamic acid (E) substitution at amino acid position 256, (iv) a proline (P) substitution at amino acid position 308,(v) a tyrosine (Y) substitution at amino acid position 434;(vi) a glutamic acid (E) substitution at amino acid position 267, and (vii) a phenylalanine (F) substitution at amino acid position 328.

71. The fusion protein of claim 70, wherein the antibody lacks an asialoglycoprotein receptor (ASGPR)-binding moiety.

72. The fusion protein of any one of claims 70-71, wherein the modified Fc domain comprises one or more members selected from the group consisting of a leucine (L) at amino acid position 234, a leucine (E) at amino acid position 235, and a proline (P) at amino acid position 329.

73. The fusion protein of any one of claims 70-72, wherein the modified Fc domain comprises a phenylalanine (F) at position 243, a valine (V) at position 264, or both.

74. The fusion protein of any one of claims 70-73, wherein the modified Fc domain comprises one or more members selected from the group consisting of a threonine (T) at amino acid position 250, a methionine (M) at amino acid position 428, an asparagine (N) at amino acid position 434, and an asparagine (N) at amino acid position 325.

75. The fusion protein of any one of claims 70-74, wherein the modified Fc domain comprises at most 8 amino acid substitutions as compared to the wild-type Fc domain.

76. The fusion protein of any one of claims 70-75, wherein the modified Fc domain comprises at most 7 amino acid substitutions as compared to the wild-type Fc domain.

77. A pharmaceutical composition comprising: the modified Fc domain of any one of claims 1-39, the fusion protein of any one of claims 40-53 or 70-76, or the antibody of any one of claims 54-69; and a pharmaceutically acceptable carrier.

78. A polynucleotide encoding the modified Fc domain of any one of claims 1-39, the fusion protein of any one of claims 40-53 or 70-76, or the antibody of any one of claims 54-69.

79. A vector comprising the polynucleotide of claim 78.

80. An isolated cell comprising the polynucleotide of claim 78 or the vector of claim 79.

81. A method of producing the modified Fc domain of any one of claims 1-39, the fusion protein of any one of claims 40-53 or 70-76, or the antibody of any one of claims 54-69, comprising incubating the isolated cell of claim 80 under a condition for the isolated cell to express the modified Fc domain or the fusion protein.

82. A method of treating an autoimmune disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the modified Fc domain of any one of claims 1-39, the fusion protein of any one of claims 40-53 or 70-76, or the antibody of any one of claims 54-69.

83. The method of claim 82, wherein the autoimmune disease is an IgA-mediated disorder, or anti-NC16A (BP180) autoantibody-mediated disorder.

84. The method of claim 83, wherein the IgA-mediated disorder comprises IgA nephropathy (IgAN), IgA vasculitis (Henoch-Schonlein purpura), linear IgA bullous dermatosis, dermatitis herpetiformis, IgA pemphigus, or IgA autoimmune hemolytic anemia.

85. The method of claim 83, wherein the anti-NC16A autoantibody-mediated disorder comprises autoimmune blistering disease.

86. The method of claim 85, wherein the autoimmune blistering disease comprises bullous pemphigoid, pemphigoid gestationis, mucous membrane pemphigoid, or drug induced bullous pemphigoid disease or disorder.